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As there is even yet a lingering doubt in many minds with regard to
some trees, whether they bear flowers and seed or not, it is the more
important to show not only that they do, but for what purpose.
—Henry David Thoreau: Faith in a Seed
The year 1997 marked three decades of coronary artery
bypass surgery. Thousands of papers have been published. I
will try to summarize the principal steps taken toward myocar-
dial revascularization, focusing the analysis on the main issue
of our daily practice: how to offer our patients proper treat-
ment based only on scientific knowledge, avoiding personal
bias. Naturally, I will concentrate on controversial areas.
Brief Historical Summary
Direct myocardial revascularization is the consequence of
the monumental work that Mason Sones and collaborators
carried out at the Cleveland Clinic beginning in 1958, when
selective coronary angiography was introduced (1). On January
5, 1962, Effler and his team (2) were able to repair a severe
obstruction of the left main trunk coronary artery by the patch
graft technique developed by Senning (3). The same month
Sones demonstrated for the first time that Vineberg’s concept
was correct: by means of collateral circulation the implanted
left internal mammary artery could ameliorate the myocardial
perfusion deficit of the anterolateral wall of the left ventricle
due to a severe obstruction of the left anterior descending
branch of the left coronary artery.
I was extremely fortunate to arrive at the Cleveland Clinic
in February 1962 and to become part of a team led by William
Proudfit in the Department of Clinical Cardiology, Mason
Sones in the Cardiovascular Laboratory, and Donald B. Effler
in the Thoracic and Cardiovascular Surgery Department.
There was a unique collection of hundreds of excellent-
quality cine coronary angiographies kept at the basement in
Sones’ Laboratory. I spent long hours at night, once duties as
a fellow of the Department of Thoracic and Cardiovascular
Surgery were over.
Very soon it became clear that two distinct groups of
patients could be recognized: (a) those with diffuse disease,
with or without collateral circulation, and (b) those with
localized obstructions, mainly in the proximal coronary
branches. Analysis of the left ventriculogram demonstrated
correlation between the severity of the coronary disease and
the state of the left ventricle. As a result the surgical approach
was directed to application of the Vineberg approach (4–6),
direct repair with the patch repair technique and reconstruc-
tion of the left ventricle when indicated (7).
In 1966 I was able to dissect the internal mammary artery
through a midline anterior thoracotomy with the aid of a
special self-retaining retractor (8). The technique allowed us to
dissect both right and left internal mammary arteries, giving
birth to the double Vineberg approach (9,10). Later it contrib-
uted to the utilization of the mammary artery as an arterial
conduit for direct myocardial revascularization. The utilization
of the midline anterior thoracotomy also allowed us to perform
combined simultaneous procedures (11) particularly in pa-
tients with abnormal ventricles (ventricular aneurysmectomy
or scar tissue resection) or patients with valvular diseases,
introducing new concepts based mainly on the overall analysis
of patients with coronary arteriosclerosis.*
As previously mentioned, direct myocardial revasculariza-
tion was performed at the beginning with the patch graft
technique. A longitudinal incision was made over the obstruc-
tion and the lumen was enlarged with a patch of pericardium
utilizing a running suture. The results on the right coronary
artery were gratifying and the operative mortality was accept-
able for those days (10.5% in the first 142 patients). However,
mortality was extremely high in patients with left main obstruc-
tion (eleven deaths in fourteen patients).
Initially, only localized obstructions were selected. When
more experience was acquired, longer and longer patch recon-
structions were performed. Very soon we realized that there
was a direct relationship between the length of the repair and
the rate of postoperative thrombosis. A longer repair increased
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*A critical discussion of the Vineberg indirect revascularization may be
found in one of my books (12).
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the rate of postoperative failure because the surface we left in
the inner layer of the coronary artery was irregular and had
many crevices, inducing turbulence and precipitating thrombosis.
At the Cleveland Clinic we had gathered a broad experi-
ence with saphenous vein grafts in peripheral and renal artery
reconstruction. Early in 1967 I started thinking that by using
the saphenous vein we might overcome many of the problems
we faced. I discussed the idea with Mason Sones and collabo-
rators and we decided that initially we would try grafting in
patients with total occlusion of the right coronary artery in
whom the distal segment was perfused by collaterals originat-
ing from the left coronary artery. If for any reason the graft
occluded, the patient would not be harmed.
The first operation was performed in May 1967 on a 51-year
old woman. The right coronary artery was reconstructed by
the interposition of a segment of saphenous vein. A few
days later—Sones was very anxious to restudy her—cine-
angiography showed an excellent reconstruction of the right
coronary artery.
In the early days of our experience we realized the limita-
tion of the interposed technique. Consequently we started
placing the proximal anastomosis of coronary artery bypass
grafts (CABG) in the anterolateral wall of the aorta. We went
slowly at the beginning (13), since we were very interested in
the late evolution of the graft. My Latin enthusiasm was
restrained by Sones many times. He would say “look if they are
plugged in three months!” By the end of 1968 we knew that the
veins would remain open without dilation within a year. That
was one of our main concerns (14). By December the largest
series in the world had been accumulated (171 patients).
Significant progress occurred in 1968:
1. We were able to combine CABG with ventricular aneu-
rysmectomy or scar tissue resection of the left ventricle (12)
following ideas originating in 1966 (11).
2. CABG with concomitant valve replacement was per-
formed after the routine utilization of cine coronary angiogra-
phy in patients with valvular disease (12).
3. Emergency revascularization in impending infarction
and acute infarction (15).
4. We applied the bypass operation to the left coronary
artery (12). It was gratifying to see that a single bypass
connected to the proximal anterior descending coronary artery
could perfuse the entire left coronary artery tree. Left main
coronary obstruction had been defeated after so many years of
struggle.
5. At the end of the year I performed a double bypass (right
and anterior descending coronary artery) in our institution,
previously performed with the interposed technique in a
bifurcated right coronary artery in March 1968 (12), thus
opening the doors to the multiple bypass approach.
In 1969 the promising results from continuous observation
were compiled by Sheldon et al (16,17) in detail. The contri-
butions by W. D. Johnson et al from Milwaukee (18–21),
showing that bypasses could be placed in the distal segments of
the coronary artery distribution, widened the scope of indica-
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tions for CABG. By June 1970 (22), we had performed 1,086
CABGs in 951 patients with an overall mortality of 4.2%.
There was a transitional period during which we combined
the indirect approach (Vineberg implants) with the saphenous
vein graft. Daily experience showed that the number of single
and double implants diminished steadily as a consequence of
the increasing number of multiple bypasses (until August 1970,
196 patients underwent double, triple, or quadruple grafts with
4.1% of hospital mortality) (23).
In 1970 thanks to the superb work of George Green in New
York (24) the author started using the direct mammary
coronary anastomosis. I talked to Green on several occasions
and he told me that over 100 hours in the laboratory would be
required to learn how to use the microscope (that is the way he
did his operations). It seemed that this approach would never
be popularized and therefore I decided to dissect the left
mammary artery and connect it to the anterior descending
artery with the routine interrupted suture technique with the
only help of the lenses that we used in our daily work. Then
indications were extended to the diagonal and circumflex
branches. After I left the Cleveland Clinic in 1971, Loop et al
(25) emphasized and standardized this method and demon-
strated the excellent results on long-term follow-up (26). Of
note, in 1968 I performed a direct anastomosis with inter-
rupted suture between the right coronary artery and the right
internal mammary artery (27).
This brief historical summary would be incomplete without
mentioning that Garrett and collaborators performed the first
successful CABG in Houston on November 23, 1964 (reported
in 1973) (28). The original objective of the operation was to
perform an endarterectomy followed by reconstruction using a
venous patch. Because of some complications they decided to
solve the problem with a saphenous graft to the anterior
descending branch of the left coronary artery. The implications
of this case were not fully appreciated. They were convinced
that the saphenous vein graft could be used as a substitute
for the Vineberg approach. Several publications by Garrett,
Diethrich and collaborators from 1964 to 1967 (29–34) pre-
sented in detail how the grafts could be connected to the
descending aorta and implanted in a tunnel on the lateral and
posterior wall of the left ventricle. They began to use CABG as
a consequence of the cumulative results of the Cleveland Clinic
by mid 1968 (35–36).
The reader can find a more detailed description of the
history of CABG in three of my publications (37–39).
The Evolution of the Surgical Technique
Many changes have taken place in the operating room in
the last thirty years. If we had recorded all the conversations
during a cardiac operation in the 1970s, 1980s and 1990s, it
would be realized that different languages were spoken. This is
not the place to analyze all changes in detail but it is worth
emphasizing that improvement in the delivery of anesthesia,
excellent extracorporeal circulation system, careful monitoring
of all the physiological parameters, minimal utilization of
blood, recovery of blood elements by the Cell Saver equipment
(mainly in reoperations), new suture materials, assisted circu-
latory support during and after the operation and a wide
variety of medications to correct deviation of cardiovascular
stability have contributed to the low operative risk even though
we operate on patients with more severe coronary artery
disease and concomitant medical problems such as: (a) less
single- and double-vessel disease, more triple-vessel disease;
(b) more patients with left ventricular deterioration; (c) pa-
tients of advanced age; (d) renal insufficiency; (e) severe
hypertension; (f) diabetes; (g) unstable angina; (h) emergency
and urgent operations, and increased number of reoperations
(40–67). If I had to choose one contribution that has changed
our lives as cardiovascular surgeons, undoubtedly it would be
myocardial protection (68–70).
The introduction of percutaneous transluminal coronary
angioplasty (PTCA) has played a significant role in the spec-
trum of the surgical population, not only because it is per-
formed mainly in patients with single- and double-vessel
disease but also because it is applied in the low risk three-
vessel-disease group. On the other hand, it has increased the
number of emergency CABGs. Naunheim (59,67) has shown
that the clinical profile of the PTCA population in the year
1985 closely resembles the low-risk profile of the CABG
patients in the year 1975.
It is futile to evaluate raw mortality data without appropri-
ate risk stratification. As an example the overall CASS (Cor-
onary Artery Surgery Study) operative mortality was 2.3%
(44), but the predicted operative mortality rates varied from
1.4% to 5.1% in relation to the risk factors involved. Edwards
and collaborators (64) analyzed the data base of The Society of
Thoracic Surgeons using a modification of the Bayesian algo-
rithm. It comprised patients operated between 1980 and 1990.
They found a steady increase in the average age (58.5 vs. 64.1
years in 1990), a trend toward higher proportion of women
(17% vs. 27%), an increased number of reoperations (1.9% vs.
7%), a progressive deterioration of ventricular function (aver-
age ejection fraction 0.62 in 1980 and 0.51 in 1990), and an
increased number of emergency and urgent operations (4.1%
vs. 18.2%). The overall operative mortality was 3.2%. Never-
theless it is important to note that between the ages of 50 and
70 the mortality was 2.6%. In patients over 70 it increased to
6%. In the first operation elective surgery carried a mortality of
2.2 vs. 5.7% among emergency patients. In reoperations the
values were 5.3 and 12.6% respectively. They concluded that
since the mid 1980s the CABG patient population had ex-
panded to those with prognostically important adverse charac-
teristics mainly older age, ventricular dysfunction, associated
diseases and surgical priority. The selected Bayesian model has
proved effective in this clinical context and has an extreme
flexibility in accommodating temporal changes in the popula-
tion (57,61). It could serve as a benchmark representing a
standard care of the national experience. Individual institu-
tions may classify their patient populations to obtain a direct
risk-adjusted comparison of results.
In another publication (66) that comprises 205,778 patients
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operated between 1984 and 1993, they found no significant
changes since 1990 in the distribution of risk factors. Six
categories of predicted operative mortality were identified
from 0 to 2.5% up to 30% to 50% risk. In Table 1 the
lowest-risk group (0 to 2.5%) decreases 17.5%. In the second
group there was virtually no change, but there was an increase
in the highest-risk group, particularly the 10% to 20% group.
Nevertheless it is interesting to note that most of the patients
(72%) belong to the group between 0 and 5%. Since 1990 the
differences among the six categories are minimal. When the
population is examined as a whole the predicted operative
mortality of 2.9% is identical to the observed operative mor-
tality. When the validated model is applied to more recent
years, the predicted operative mortality is within the range of
5%. Even when statistical risk models have gained widespread
acceptance, they should be interpreted with knowledge and
sound surgical judgment acquired by experience (71).
The data base of The Society of Thoracic Surgeons gives an
idea of the overall practice of CABG in USA but cannot be
applied to each individual surgeon or institution. The mortality
achieved is in accordance with the type of patient accepted in
daily practice. To cite an example, if we analyze 1,000 consec-
utive patients operated on in our hospital from February 1995
to April 1st, 1996, where 214 patients were above 70 years of
age, 412 had a previous myocardial infarction (61 were oper-
ated within 30 days), 153 had history of cardiac insufficiency,
194 were diabetic, 33 had severe renal insufficiency, 580 were
hypertensive, 125 had definite lower-limb claudication, 398 had
unstable angina, 101 underwent previous myocardial revascu-
larization, 74 were operated on within three days of a PTCA,
160 were urgent operations, 47 were emergencies, 410 demon-
strated severe triple-vessel disease, 184 had left main trunk
obstruction, 273 had ejection fraction of 0.3 or less and 108 had
ejection fraction 0.2 or less. Thus, a 4.5% mortality is amply
justified.
Therefore it is not adequate to present the raw mortality
data without analyzing the surgical population properly. It may
lead to a general misconception. Increased mortality is not
always related to “poor surgery.” It seems that society and
health regulation organizations are pressing for “safe” surgery.
However, it is important to realize that if all of us were
competing to show low operative mortality, there is no doubt
that the moderate and high-risk patients will be denied the
chance of undergoing operation.
In summary, review of the literature demonstrates that
since 1985 the subset of patients referred for CABG has
evolved into a population with a high incidence of advanced
age, severe coronary artery disease, left ventricular dysfunc-
tion, and various concomitant medical problems. Urgent and
emergency procedures continued to increase in frequency.
Campeau (72,73), Bourassa (74) and Grondin (75) demon-
strated the deterioration of the saphenous vein in time mainly
because of arteriosclerotic changes, and Loop (26) showed
—after comparing 2,306 patients who received a mammary
graft to the anterior descending branch of the left coronary
artery, plus one or more saphenous vein grafts, with 3,625 who
had only saphenous vein bypasses—that at ten years there was
a clear advantage of the group with mammary artery grafts in
patients with single-, double-, or triple-vessel disease even
among those with moderate or severe left ventricular impair-
ment. Many additional contributions have shown (24,76–155)
that arterial bypasses with one or two mammaries are the grafts
of choice. It is worth mentioning that up to 1980, only 13% of
the surgeons were using mammary grafts (91). Since the mid
1980s the number has increased steadily and today most
surgeons employ them.
Review of the literature has clearly demonstrated that,
when internal mammary arteries are utilized:
1. the operative mortality and the rate of perioperative myo-
cardial infarction decrease, even at reoperations;
2. the patency rate (early and late) is higher than when
saphenous vein grafts are utilized;
3. the major events, mainly myocardial infarction, are less
frequent;
4. they become an independent predictor of late survival in all
categories of patients and should not be denied in any
subgroup: older and younger patients, men or women,
normal or impair ventricles, single-, double-, triple- and
left-main-trunk obstruction;
5. the maximal diastolic flow velocity is higher than that in
saphenous vein grafts.
6. they adjust to physiological demands and clearly enlarge
overtime;
7. they improve left ventricular performance;
8. they improve exercise tolerance;
9. they resist degenerative changes.
It should be emphasized that the use of these grafts is
certainly possible in elderly patients. Reports in the literature
(122–124,153) and our own experience show that the mam-
mary artery remains free of atheromatous changes in patients
over 70 years of age. It also can be used in emergency
revascularization operations, including patients with failed
angioplasty (156–166). With appropriate technical skill, the
dissection of the mammary artery will not take more than 10
minutes. It is important to realize that we do not have to
perform a proximal anastomosis. As a consequence the anoxic
Table 1. Predicted Mortality for Patients Undergoing CABG From
1984 to 1993*
No. of
Patients
Risk
Stratification
Difference
Between
1984 and 1993
99,332 0% to 2.5% 217.5%
47,191 2.5% to 5% —
31,278 5% to 10% 16.2%
22,218 10% to 20% 19.1%
2,767 20% to 30% 11.4%
2,035 30% to 50% 11.1%
*Data from Clark et al. (66). CABG 5 coronary artery bypass graft surgery.
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time will be equal to that utilized in the construction of a
saphenous graft.
Due to the excellent results of the internal mammary graft,
surgeons looked for other sources of arterial conduit. The right
gastroepiploic artery was first utilized in myocardial revascu-
larization by Bailey and associates for a Vineberg type opera-
tion (167). In 1987 Pym (168), Suma (169) and Attum (170)
reported the early application of the gastroepiploic artery for
direct myocardial revascularization. Later Mills (171) and
Lytle (172) confirmed good clinical and angiographic results.
Several publications promoted the utilization of this vessel
(173–181). Use of the inferior epigastric artery was introduced
by Puig (182) in 1990, mainly applied in grafts to the diagonal,
lateral branches of the circumflex and right coronary artery.
Afterward several contributions (183–190) analyzed its practi-
cal application.
Recently Buche and associates (191) presented their expe-
rience with arterial revascularization in which 167 distal anas-
tomoses were connected to the inferior epigastric artery with
excellent early patency rate. At an average of 8.5 months, 44 of
the 48 inferior epigastric artery grafts were patent, but eight
showed some narrowing. Schroeder and collaborators (192)
reported an early patency rate of 90% (ten days from the
operation) and 84% at 24 months.
In 1971 Carpentier introduced the radial artery as an
alternative for coronary artery bypass. His early experience was
reported in 1973 (193). Two years later he advised that its use
be discontinued because of a 30% incidence of graft occlusion.
Nevertheless 18 years later a patient in whom postoperative
arteriography showed total obstruction was restudied and
surprisingly the radial artery was fully patent with no evidence
of atherosclerotic changes. Three other patients had similar
cine coronary angiographic findings. It seems logical that
arterial spasm was the cause of the “early obstruction” of the
graft.
Consequently, in 1989, Carpentier’s group (194,195) re-
vived the use of the radial artery, adding the administration of
calcium channel blockers during and after the operation. Up to
January 1995, three hundred and twenty-seven patients were
revascularized with the radial artery in addition to internal
mammary arteries. Postoperative angiography in 141 patients
between one month and one year showed a 92% patency rate.
A recent long-term follow-up (mean 5.4 years) in 100 patients
demonstrated a patency rate of 84.2% (personal communica-
tion with Acar).
After the French experience the radial artery is utilized in
most of the cardiovascular centers. A detailed description of
the technique of harvesting the radial artery can be found in a
paper by Reyes and collaborators (196). The Allen test is
mandatory preoperatively and after the exposure has been
performed, in order to avoid any possible ischemic complica-
tions in the hand (197).
The concept of anastomosing another bypass graft to an
attached internal thoracic artery was introduced by Mills (198)
in 1982 to avoid placing it into a severely atherosclerotic
ascending aorta. Sauvage (137) employed a similar approach to
bypass all coronary arteries and Tector emphasized its advan-
tage in 1989 (142,199).
Calafiore, a pioneer in utilizing composite grafting
(200,201), said that “these arteries are normally third- or
fourth-order branches of the aorta, so they are usually submit-
ted to a pattern of flow that is quite different and therefore
cannot tolerate the flow of the ascending aorta. When these
conduits are anastomosed to the aorta the abrupt increase in
pressure wave can result in wall stretching with intimal tearing
and subsequent development of premature hyperplasia” (200).
Certainly the rate of rise of left ventricular pressure in their
natural position is different from that in the ascending aorta.
At present different options can be utilized for multiple
arterial coronary revascularization. In our department of tho-
racic and cardiovascular surgery we follow this pattern:
1. Both internal mammary arteries in situ are used, with or
without distal sequential anastomosis. Very seldom do we use
more than two for each mammary artery. The right one is
generally placed through the transverse sinus as suggested by
Puig in 1984 (101). The author believes that it is mandatory to
connect both mammary arteries to the left coronary artery
distribution.
2. In order to reach distal coronary branches, the right
mammary artery is anastomosed to the left mammary artery
end-to-side. Rarely do we connect a mammary artery to the
ascending aorta.
3. The radial artery is our next choice, anastomosing it to
the left mammary artery. All the distal lateral branches of the
circumflex coronary artery and even the distal distribution of
the right coronary artery can be reached (Fig. 1).
4. Because of its length, the inferior epigastric artery (we
use only the proximal portion), is connected to one of the
mammary arteries and, distally, mainly to diagonal and lateral
branches of the circumflex (Fig. 2).
Figure 1. Solid arrow indicates left internal mammary artery anasto-
mosed to the anterior descending branch of the left coronary artery.
Open arrows indicate radial artery with a proximal anastomosis to the
left internal mammary artery and connected afterward to the three
circumflex artery branches.
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5. The gastroepiploic artery is utilized, with less frequency,
mainly for the distal distribution of the right coronary artery.
We try not to “hang the heart” (202) on a single internal
mammary artery by connecting all the other bypasses to it,
even though postoperative studies confirm that the artery
enlarges significantly when multiple distal anastomoses are
connected to a single internal mammary artery. Two sources of
inflow are preferable. Of course saphenous vein grafts are still
utilized, mainly in older patients; although they deteriorate in
time, 35.7% are still open 22 years later (203).
It is worth emphasizing that the internal mammary artery
remains the graft of choice and is our first option. Physiological
and histological studies confirm its advantage (204–215).
The fear of increasing sternal disruption proves groundless
if we dissect the artery properly, avoiding wide pedicles that
must be dissected with careful utilization of the electrobis-
toury. Excessive burning is the most important cause of
postoperative complications. Except in diabetic patients, the
rate of infection—mainly mediastinitis—is not increased, even
when both mammaries are utilized.
Although there is not total agreement that the utilization of
both mammary arteries results in longer survival, Cosgrove and
collaborators (216) clearly demonstrated that among patients
under 60 years of age their utilization is preferable.
In the early days we were able to accomplish CABG on a
beating heart without the pump (14,217–219) to the right
coronary artery or the anterior descending branch of the left
coronary artery in a small, select group of patients. Afterward,
in 1975, Trapp and Ankeney reported a similar approach
(220,221). Benetti (222–225) and Buffolo (226,227) operated
on a significant number of patients with a low operative
mortality. It is worth mentioning that the 1,274 patients
operated on by Buffolo (228) represented 20.3% of the total
number of patients submitted for CABG in his hospital. Most
of the grafts were placed on the right coronary artery (RCA)
(659 grafts) or the left anterior descending (LAD) (365 grafts).
Only 130 distal anastomosis were placed on lateral or dia-
phragmatic branches; 7.7% underwent three bypasses. The left
internal mammary artery (LIMA) was utilized in 42.9% of the
grafts. They emphasized that “the technique is particularly
suitable for patients with lesions in the LAD or RCA.” A
seven-year follow-up was presented at the seventy-seventh
Annual Meeting of the AATS held in May 1997, which
compared 107 patients operated on a beating heart (BH) with
122 patients operated on with cardiopulmonary bypass (CPB)
during 1989. The final decision was often taken in the operat-
ing room. A total of 260 vessels were bypassed in the BH group
vs. 362 in the CPB group. Almost all patients had a bypass
performed to the LAD branch (88% vs. 86% BH and CPB,
respectively). A high proportion of obtuse marginal (100% vs.
62%) and posterior descending vessels (46% vs. 16%) were
bypassed in the CPB group. At seven years 80% of the BH
group and 79% of the CPB group were alive. But 16 patients
of the BH group underwent PTCA and five repeat CABG.
Only five patients of the CPB group had PTCA. Even though
only 34 patients were catheterized, the patency rate demon-
strated a significant higher rate of patency in the CPB group
(72 vs. 34%). They conclude that
Parity between groups was achieved only by using three times as
many post bypass interventions in the BH group. It would
appear that beating heart bypass produces results intermediate
between conventional bypass (best) and angioplasty (worst). It
further suggests that limited revascularization, by either PTCA
or BH bypass will produce long-term results comparable to full
revascularization, if one accepts the need for additional proce-
dures later.
It should not be forgotten that Kolessov in Russia per-
formed a mammary coronary anastomosis without extracorpo-
real circulation in 1965 (229).
Personally, I believe it will be extremely difficult to perform
the present technique of multiple composite arterial bypasses
on a beating heart if we realize that, to obtain good results, a
meticulous and delicate technique with 8–0 running sutures
must be utilized. Perhaps this will be possible in the hands of
a few privileged master surgeons who cannot be emulated by
most of us.
Recently, a less traumatic operative technique was intro-
duced (230–235): a single internal mammary artery graft to the
anterior descending branch of the left coronary artery can be
accomplished without extracorporeal circulation through a
small left anterolateral thoracotomy. Calafiore et al popular-
ized this technique and reported the world largest series (236).
If we bear in mind that this is the most important branch of the
coronary circulation, this new approach constitutes a signifi-
cant step forward. Patients can be discharged within two or
three days, significantly reducing the cost. The number of
patients can be increased if we combine it with PTCA for
localized obstructions of the right coronary artery or circumflex
branches of the left coronary artery. In some patients a
Figure 2. Long arrow indicates left internal mammary artery anasto-
mosed to the anterior descending branch of the left coronary artery.
Short arrows indicate epigastric artery with a proximal anastomosis to
the left internal mammary artery and connected afterward to two
circumflex artery branches.
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composite graft to the diagonal branch of the left anterior
descending branch can be accomplished utilizing small seg-
ments of the epigastric artery.
It is possible that thoracoscopy will play a role in dissecting
arterial conduits. Automatic suture stapling devices, laser
welding or gluing for construction of the anastomoses may
become feasible. It is too early to make any prediction, but we
should be always open to new ideas and development, under-
standing that judgment and criteria are necessary to evaluate
them properly.
The Controversies
Initially it was extremely difficult to convince our medical
colleagues that a very simple operation could ameliorate the
myocardial perfusion deficit, even when several observations
confirmed that the delivery of oxygen is enhanced by CABG
(237–261). Probably the main reason was the failure of previ-
ous attempts of myocardial revascularization, starting with
Jonnesco’s ideas (262,263). In most of them the indications and
results were judged only on a clinical basis and since Proudfit,
Shirey and Sones’ contribution (264), where they correlated
the results of the clinical and electrocardiographic diagnosis
with findings of cine coronary angiography in 1,000 patients,
we know that in approximately 20% of the patients the clinical
impression may be wrong.
After the introduction of cine coronary angiography the
natural history of coronary arteriosclerosis is better under-
stood. Several studies (265–272) have clarified the prognosis of
patients with single-, double-, triple-vessel disease and left
main trunk obstruction and their relation with the left ventric-
ular status. Cine coronary angiography allows us: (a) to
confirm or exclude the diagnosis of coronary arteriosclerosis;
(b) to evaluate the degree and distribution of the occlusive
disease; (c) to select the proper candidates for revasculariza-
tion procedures, and (d) to obtain an objective evaluation of
the postoperative result.
The early surgical experience of the Cleveland Clinic in 741
patients operated on from May 1967 through December 1970
was carefully evaluated by Sheldon and collaborators (273).
The hospital mortality rate was 3%. Perioperative myocardial
infarction occurred in 6.9% of the patients. All survivors were
followed for 36 to 85 months (average 45.8). Forty-seven
patients died during this period (28 due to cardiac causes).
Postoperative angiographic studies showed a patency rate of
77.3% (79.5% of grafts connected to the anterior descending
branch of the left coronary artery) at a mean interval of 16.2
months. New proximal occlusions occurred in 33% of the
grafted arteries: 87.7% occurred in arteries that were severely
stenosed 80% to 90% in the proximal segment preoperatively.
The survival of the surgically treated group was compared with
a medical group compiled by Webster and collaborators (272)
who had cine coronary angiography from 1960 through 1965.
The average annual attrition rate was 3.5%, 9.8% and 19.3%
for single-, double- and triple-vessel disease in the medically
treated group. The surgical group, including hospital mortality,
had, respectively, 2.4%, 4.6% and 4.6% attrition annually for
single-, double- and triple-vessel disease.
The medical survival curves were similar to a study under-
taken by Bruschke (268), but Webster’s data were chosen
because they included patients who had been considered
candidates for graft surgery by criteria applied in 1970, mainly
severe proximal obstructions. It was clear that patients with
double- and triple-vessel disease were highly benefited by
surgery. In patients with single-vessel disease the difference did
not have statistical value with the exception of proximal
obstruction of the left anterior descending branch. The attri-
tion rate per year of this group was 1.7% for the surgical
patients and 4.8% for medical. Patients with moderate impair-
ment of left ventricular function were also benefited. Eighty-
nine percent of these patients survived three years compared
to 94% of survivals among patients with normal or mild
deterioration. Complete revascularization was achieved in
more than half of the patients studied: 87% were asymptom-
atic on evaluation. On the other hand, in patients with
incomplete revascularization, only 42% remained asymptom-
atic, and 32.8% had angina class II. The surgical group
demonstrated definite improvement on exercise tolerance test-
ing. This report summarized our early experience at the
Cleveland Clinic (learning period). Several reports confirmed
these preliminary data (18,35,274–286). By 1974 hospital mor-
tality decreased to 1.4%, perioperative myocardial infarction,
to 4.1%, and graft patency rate increased to 83.6% (eighty-nine
percent of the patients had one or more functioning grafts).
The early occlusion rate (5% to 15% at one month) (287–289)
diminished steadily with the administration of aspirin and
dipyridamole suggested by Chesebro et al (290,291).
Nevertheless the opinions were highly divided; on the one
hand, the enthusiasts (273,283,292–317), on the other, the
opponents and colleagues who had sounded a word of caution
(281,318–348).
Three methods were used to compare the long-term effect
of coronary bypass surgery with medical treatment up to 1977:
1. Retrospective matched studies. The surgery performed
during the 1970s had been compared to the evolution of the
patient treated medically in the 1960s. There were two prob-
lems: (a) it was difficult to match the patients because of
selection bias, and (b) it was difficult to assume that the
medical management used during the 1960s had remained the
same during the 1970s, when medical treatment had improved.
Even so, we have to recognize that already in the 1960s there
was a decline of 18.4% in the death rate of ischemic heart
disease. The advantage of this method was that we could select
patients with the same angiographic pattern in an era when
CABG was not performed.
2. Prospective matched studies. This method entailed creat-
ing a protocol and entering patients into the study as they were
observed. Nevertheless selection bias might occur and influ-
ence the entry of patients; it did not guarantee that all the
variables were equalized, mainly the number and precise
location of the obstruction at the coronary level.
3. Comparison of study groups with life tables. It was possible
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to estimate the yearly survival rate of persons living in the
United States with the life table generated in the Department
of Health Education and Welfare or by tables from insurance
companies and compare them to the survival curves of the
study group. Some critics stated that the number of patients of
the study group was small when compared with the general
population and might not be a representative sample.
A critical analysis of the first ten years of CABG from two
different points of view can be found in a contribution by J.
Willis Hurst and collaborators (311) in which the value of the
new surgical approach is emphasized, and in a special article by
McIntosh and Garcı´a (349), a collection of papers highly
critical of CABG. As an example of one of them, Achuff and
collaborators (329) questioned whether alleviation of angina
was due to a patent graft or to a new myocardial infarction to
the “angina-producing” segment. They reported 71 patients
(7.8% operative mortality) mainly with single and double
bypasses (only four triple grafts) and a 63% postoperative
damage!
On March 7, 1978 in the Louis F. Bishop Lecture at the
27th Meeting of the American College of Cardiology (316) I
analyzed the myths and realities of a ten-year journey. In 1977
we had clear evidence that the new blood supply: (a) improved
myocardial performance; (b) relieved angina pectoris; (c)
improved the quality of life; (d) prolonged life in properly
selected patients with left main coronary obstruction, double-
and triple-vessel disease, including patients with abnormal
ventricles and lower ejection fraction; (e) diminished the
incidence of sudden deaths; and (f) appeared to decrease the
incidence of myocardial infarction. The percentage of periop-
erative myocardial damage played a significant role when the
comparisons were made.
The Randomized Trials
During the first ten years of CABG the discussions between
cardiologists and cardiovascular surgeons emphasized the need
of randomized trials, which indeed appeared in the last part of
the decade.
The first randomized trial was the Veterans Administration
(VA) cooperative study. A preliminary report of a subgroup of
patients with significant left main lesions (113 patients from
January 1970 through December 1974) demonstrated a signif-
icantly higher survival of the surgical patients. In September
1977 (350) they released the first publication of their overall
population with three-year survival. Afterward, several contri-
butions (351–363) compared the results at different intervals
up to an eighteen-year follow-up.
A total of 5,538 patients with stable angina were screened,
2,125 had coronary arteriography and 1,015 patients were
randomized. Reading of the cineangiographic films was com-
plicated. After an initial study revealed considerable interob-
server and intraobserver variability in interpretation, all coro-
nary angiographies were reread by each observer, using a
standardized data sheet. Data presented in that report were
based on the second-reading information. Goffredo Gensini
was asked (personal communication) to review the coronary
angiographies of patients included in the study. He later wrote
to Marvin Murphy, stating
I am sure you will agree that some of the early films hardly
show the outline of the coronary arteries at all, thus the
determination of the size, degree of stenosis and the surgical
adequacy of the runoff is quite chancy at best. Under such
circumstances I believe that a not insignificant number of
patients were randomized to either medical or surgical therapy
when they should not (or could not) have been selected for
surgery in the first place. If you assume for a moment that a
statistically significant number of patients had surgery when
either the runoff was inadequate or the bypass was unnecessary,
it would not be surprising to find no difference between medical
and surgical therapy. In fact, these patients when randomized to
surgery would tend to have poor results.
Patients with (a) myocardial infarction less than 6 months
before operation; (b) persistent diastolic hypertension (more
than 100 mm Hg) despite treatment; (c) marked cardiac
enlargement; (d) previous operation for angina pectoris; (e)
unstable angina or angina of increasing severity, suggesting
“impending infarction”; and (f) congestive heart failure unless
clinically compensated for at least three weeks, were excluded
(352). Some degree of abnormal left ventricle contractility was
observed in 53.5% of the surgical group and 55.3% of the
medical group. Nevertheless only 15% of both groups had an
ejection fraction below 0.45.
A high risk patient was defined as one with three-vessel
disease and some abnormality of left ventricular function (38%
of medical and surgical groups). A low-risk patient was defined
by default as one not in the high-risk group or one with
undetermined risk because of incomplete data (92 patients, 50
medically and 42 surgically randomized) (352). The 5.6%
operative mortality was high if we consider that approximately
two thirds were low-risk patients. Furthermore, 18% of them
had had perioperative myocardial infarction and at one year
only 69% of the grafts were open (all the grafts were occluded
in 13% of the patients). At three years there was no survival
difference between the two groups.
There was a surprisingly low mortality rate at two years in
the medically treated group with an overall survival of 90%
(88% among patients with triple-vessel disease). We did not
know how many of them had proximal obstructions. In the
early Cleveland Clinic series—where most of patients had
indeed proximal obstructions—the survival in three-vessel
disease was 66% (268,269) and 63% (272). As we will discuss
later three-vessel disease is not a single entity.
In 1981 another risk stratification was done based on four
non-invasive characteristics: New York Heart Association
(NYHA) angina class III and IV, history of hypertension,
history of myocardial infarction, and ST segment depression
on routine electrocardiography. The risk function was devel-
oped by applying the Cox-Breston life table regression model.
Patients were divided into low, middle and high-risk terciles.
At six years surgery prolonged life in the high-risk tercile.
8B FAVALORO JACC Vol. 31, No. 4 Suppl B
CRITICAL ANALYSIS OF CABG: A 30-YEAR JOURNEY March 15, 1998:1B–63B
When the analysis was restricted to the ten hospitals with lower
30-day mortality (3.3%) even the mid-risk tercile was bene-
fited.
It is interesting to note that patients that were excluded
from the original protocol were included in the high-risk group
(ST segment depression on electrocardiography, previous
myocardial infarction, history of hypertension, and angina class
III and IV) and were highly benefited by surgery.
At five years the surgically treated patients had significantly
higher relief of angina and better exercise performance; how-
ever, at seven years a gradual loss of survival benefit occurred
presumably due to increasing graft closure, and at ten years,
relief of angina and exercise performance were comparable.
Survival of the surgical angiographically high-risk group re-
mained higher than that of the medical group until the
eleventh year was reached. The cumulative rate of crossover
for medical to surgical therapy was 25%, 40%, 57% and 62%
at five, eleven, fifteen and eighteen years, respectively.
In summary, even though the VA study comprised a group
of patients selected mainly on a clinical basis (poor cineangiog-
raphy in a significant number of patients) with relatively high
operative mortality, high incidence of perioperative myocardial
infarction, and low patency rate of the bypasses performed,
when the hospitals with high operative mortality were ex-
cluded, surgery improved survival in patients with left main
coronary artery disease and patients in mid and high-risk
terciles.
The second randomized study was published in November
1978: Unstable Angina Pectoris—National Cooperative Study
with the auspices of the National Heart, Lung, and Blood
Institute (NHLBI). The first two publications (364,365) clearly
demonstrated that patients with different prognoses were
included. Thirty-six percent of the 147 medically assigned
group (49% with triple-vessel disease) were operated on at 30
months. Any final conclusions were prevented by the high
crossover rate and the small number of different subsets. In
1982 Hultgren and collaborators (366) agreed: “the high
incidence of crossover and the short follow-up time, limited the
evaluation of comparative survival data.” In 1981 they pub-
lished the results among patients with left anterior descending
coronary obstruction (367). The 9% mortality in the surgical
group and the 23% incidence of perioperative myocardial
infarction in patients with proximal anterior descending coro-
nary artery obstruction did not allow any further conclusions.
The third randomized study came from Europe and the
early results were reported in 1979 (368–372). It included only
males under 65 years of age with two or three-vessel disease
(including left main trunk obstruction) and a left ventricular
ejection fraction of 0.5 or higher. Patients with severe angina
pain that could not be controlled by medical treatment were
not included. Likewise, patients with uncontrolled arterial
hypertension were not admitted. The proportion of patients
receiving a beta blocker at the time of randomization was 74%
in the medical group and 75% in the surgical group. A
comparison was made between 373 patients included in the
medical group and 395 patients that underwent operation. The
operative mortality was 3.6%, including eight deaths that
occurred before the operation. Graft patency rate was 90%
within nine months and 77% between 9 and 18 months. At five
years 90 patients (24%) of the medical group had had a CABG
(because of disabling angina) and were kept in the medically
treated group.
At five and eight years patients with left main coronary
obstruction, and three-vessel disease—mainly when a proximal
obstruction $50% was present in the anterior descending
artery—were highly benefited by surgery. For the first time we
had clear evidence that, in patients with double-vessel disease,
surgery improved survival if the anterior descending artery had
.75% narrowing. In patients with ischemic ST segment de-
pression of .1.5 mm during exercise test, the prognosis was
significantly improved by surgery. In summary, in selected
subsets of patients with left main obstruction or double and
triple-vessel disease, surgery improved survival.
The conclusions of the Consensus Development Confer-
ence on Coronary Artery Bypass Surgery, organized by the
National Institutes of Health were reported in 1980 (373):
The symptom of angina pectoris is reported to be relieved in
80% to 90% of patients undergoing surgery for chronic stable
angina. Bypasses have reduced the subsequent number of
cardiac related events, the amount of medication required, and
the frequency of hospitalization. The majority of patients have
been able to increase their exercise capacity and improve their
NYHA functional class after operation. The operation has been
documented by improvements in functional exercise testing,
angina threshold, left ventricular wall motion, left ventricular
ejection fraction, during exercise and lactate extraction across
the myocardium. There is the conclusion of the panel that
CABG represents a major advance in the treatment of patients
with coronary artery disease. Evidence has been presented to
support the conclusions that an improvement in the quality of
life, a decrease in myocardial ischemia, and an increase in
survival have been demonstrated after CABG in selected
subsets of patients.
In the early 1980s CABG experienced real advances, with a
decrease of operative mortality and perioperative myocardial
infarction, mainly because of cardioplegia and despite the fact
that the number of high-risk patients had increased steadily.
Long-term follow-up started to show that the utilization of
internal mammary artery grafts improved later survival. At that
time the National Heart, Lung and Blood Institute organized
the Coronary Artery Surgery Study (CASS); its original pro-
tocol appeared in 1981 (374). The first data of the randomized
trial were released in November 1983 (375), and as a conse-
quence, the dispute flared up with renewed vigor.
From 15 participating clinics, eleven took part in the
randomized trial. A total of 24,959 patients were included in
the registry. Only 12.7% met the criteria for randomization.
Finally, 780 patients (4.7%), 65 years of age or younger, were
included.
As in the VA study, the accuracy of the cine coronary
angiography was not uniform. The report of the Quality
Control Committee (376) emphasized that
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the reproducibility of interpretation of films of good or accept-
able quality or completeness was better than the reproducibility
of readings of arteriographies judged to be of poor quality or
incomplete studies. When one angiographer reads a stenosis of
50% or more in the left main coronary artery, it is estimated
that a second reader will report no lesion 18.6% of the times.
The reproducibility of angiography is improved with high
quality films and complete studies. There is an indication that
differing clinics can reduce the variability between their read-
ings by concerted effort to improve both the quality and the
completeness of the angiographic examination.
Furthermore the anterior descending artery was considered
diseased if 70% or greater stenosis was present in segments 12,
13, 14, 15 or 16 (above the first septal perforation, below the
first septal perforation, mid portion, first diagonal and second
diagonal). This approach may be inappropriate, because the
prognosis would vary significantly in relation to the different
locations (310,377–380).
Evaluation of the left ventricle was done, but although the
clinical sites were encouraged to obtain a 60% to 70% left
anterior oblique, only the right anterior oblique view was
utilized in CASS publications (381). Therefore the entire
lateral wall of the left ventricle was not considered. The wall
motion score, the myocardial jeopardized index, the corrected
ventricular score and the residual left ventricular score utilized
in CASS protocols gave only a partial interpretation of the left
ventricular status. Thus the reading of the left ventricular
aneurysm was confusing (381):
In absolute terms, the agreement between the quality
control centers and clinical sites with respect to reading left
ventricular aneurysms was poor. When one observer indicated
the presence of left ventricular aneurysm, the other observer
agreed that there was an aneurysm of the same segment in 26%
of cases. However, when ‘nearest neighbor’ differences were
excluded, the agreement was much better. When one observer
read the presence of a left ventricular aneurysm, the other site
read either an aneurysm or dyskinesis of the same or an
adjacent segment in 77% of cases.
The consideration of left ventricular aneurysm in the CASS
registry became even more confusing when they reported the
surgical experience accumulated (382). Of 1,131 who were
enrolled in the registry, 467 underwent surgery and only 238
had ventricular resection!
The characteristics of the randomized population (the first
patient was assigned in August 1975 and the last in May 1979)
are described in Table 2. The clinical and angiographic char-
acteristics (Table 3) demonstrate that the randomized patient
belonged to a low-risk group (383):
1. Mild angina was present in 620 patients and no angina in
160 patients, altogether representing only 4.7% of the 16,626
patients originally screened.
2. Ejection fraction above 0.50 was present in 74% of
patients. Only 160 patients had moderate impaired deteriora-
tion: 0.35 to 0.50, and the mean ejection fraction of the 780
patients measured was 0.61.
3. There was a modest extent of coronary artery disease:
67% had one or two-vessel disease and we only know that 31%
showed proximal left anterior descending coronary artery
obstruction (only half of the number included in the European
Coronary Artery Study). No data are available in the original
article relative to proximal obstruction on the right and
circumflex coronary arteries. Nevertheless, if we carefully read
Table 2. Clinical Characteristics of Subsets for Randomization in CASS*
No. of
Pts
General
Description Angina
Heart
Failure
Ventricular
Function
Previous
MI
514 Mild angina with normal left
ventricular function
Mild (CCS class I or II) Absent LVEF $ 0.50 or normal pattern in at
least 4 or 5 segments (RAO
ventriculography)
Yes or no
(.3 wk)
106 Mild angina with left
ventricular dysfunction
Mild (CCS class I or II);
primary problem, angina
If present, not primary
problem and not
decompensated
LVEF 5 0.35–0.50 or abnormal pattern
in $2 of 5 segments (RAO
ventriculography)
Yes or no
(.3 wk)
160 Asymptomatic after MT Asymptomatic If present, not
decompensated
Not a criterion for this group, but likely
to be normal
Yes
*Data from reference 375. CASS 5 Coronary Artery Surgery Study; CCS 5 Canadian Cardiovascular Society; LVEF 5 left ventricular ejection fraction; MI 5
myocardial infarction; Pts 5 patients; RAO 5 right anterior oblique.
Table 3. Clinical and Angiographic Characteristics of 780 Patients
From the CASS Randomized Trials*
Characteristic % of Pts
CCS class I angina 65.9
CCS class II angina 13.6
No angina symptoms 20.5
LVEF .0.5 73.7
LVEF 0.35–0.5 20.5
1- or 2-vessel disease 66.9
3-vessel disease 33.1
3-vessel disease with 3 proximal obstructions 1.0
LMCA equivalent 5.2
LAD proximal lesion .70% 31.5
Proximal obstruction of Cx or RCA Unknown
Induced ischemia 40.0
*Data from Favaloro (383). Cx 5 circumflex coronary artery; LAD 5 left
anterior descending coronary artery; LMCA 5 left main coronary artery;
RCA 5 right coronary artery; other abbreviations as in Table 2.
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the publication from CASS related to the surgical treatment of
“left main equivalent” (384) we will see that 41 patients
(5.25%) had concomitant proximal left anterior and circumflex
lesions in the very proximal segments in the randomized trial,
and only 51 patients (3.87%) of 1,315 patients in the random-
izable group, suggesting that only a minimal number of pa-
tients with proximal obstruction were included in the random-
ized and randomizable groups. This was further highlighted in
the CASS contribution presented by Myers and collaborators
at the 22nd Annual Meeting of the Society of Thoracic
Surgeons (January 1986) (385): of 195 patients with triple-
vessel disease and normal ventricle included in the randomized
series, only 8 (two in the medically treated group and six in the
surgically treated group) had three proximal stenoses. It is
logical to think that the majority of patients included in the
randomized trial with triple-vessel disease had very few prox-
imal obstructions.
4. Further evidence that the trial was a low-risk group is the
fact that only 40% of the patients had exercise-induced myo-
cardial ischemia.
The operative mortality was 1.4%. Perioperative myocar-
dial infarction occurred in 6% of the 357 surgical patients. All
patients were followed for 3.8 years, 69% for five years, 40%
for six years and 11% for seven years. Consequently all the
data analyzed are derived by actuarial analysis.
At five years there was no difference of outcome between
the medical and surgical groups. The five-year mortality in
patients assigned to surgical therapy was 5.5% (1.1% per year).
In patients with single-vessel disease it was 3.5% (0.7% per
year); in double-vessel disease, 5% (1% per year); and 7.5%
(1.5% per year), in patients with triple-vessel disease. In
patients with ejection fraction less than 0.50% the five-year
mortality was 8.5% (1.7% per year). In patients assigned to
medical therapy the five-year mortality was 8% (1.6% per
year). In patients with single-, double- and triple-vessel disease,
the five-year mortality was 7% (1.4% per year); 6% (1.2% per
year) and 10.5% (2.1% per year). In patients with an ejection
fraction less than 0.50 the five-year mortality was 16.5% (3.3%
per year).
Therefore the message (375) was that
In patients similar to those enrolled in the CASS trial, a
strategy of medical management until worsening symptoms
require surgical palliation does not carry a mortality penalty.
Furthermore, deferring surgery does decrease immediate
health care costs and preserve both veins and mediastinum if
surgery is required later. Thus, the decision to proceed with
bypass surgery in these patients can be reduced to the question
of whether the current level of symptoms is acceptable to the
patient. These findings have important implications for both
cardiologists and cardiac surgeons in their diagnostic and
therapeutic efforts.
Once more as in the previous randomized trials, patients
were considered to belong to the therapeutic group to which
they were initially assigned (intention to treat) regardless of
the subsequent therapy received (386). Accordingly, of 390
patients assigned to receive medical therapy, 23.5% (4.7% per
year) had bypass surgery within five years. The crossover rates
were 10%, 21% and 38%, respectively for single-, double- and
triple-vessel disease. As we previously mentioned, only 69% of
the patients were followed for five years, leaving the possibility
that more patients might cross over by the time full five-year
follow-up was completed. A total of 280 patients (74.4%) in
the medically treated group followed their assigned therapy.
The operative mortality in patients assigned to medical therapy
but subsequently undergoing surgery was 2 in 100. More than
50% were patients with triple-vessel disease (386). I think we
have to agree that by following the intention-to-treat policy,
the medically treated group was highly benefited.
If we are to compare two different therapies, crossover
represents failure of medical treatment. Using this approach in
patients with three-vessel disease, Rahimtoola (387) included
death, myocardial infarction and crossover as events in the
medically assigned group and death and myocardial infarction
in the surgically assigned group. The failure rate was 61% in
the medically assigned group and 22% in the surgically as-
signed group.
Willis Hurst had clearly emphasized in an editorial (388)
that the CASS report was “overshadowed” by general misin-
terpretation. But certainly, it impacted our colleagues. As an
example, in six counties of the Rochester area (389), catheter-
ization decreased 19% and CABG, 13%.
Another article from CASS (390) clearly demonstrated that
the quality of life improved in the surgically treated group as
manifest by relief of chest pain, subjective and objective
improvement of the functional status (there was a remarkable
fall in the percentage of treadmill-induced ischemia at 6, 18
and 60 months), and a diminished requirement for drug
therapy.
The publication of the CASS data produced a significant
impact in our field and even among the general population
when articles appeared in the lay press. The fact that CASS
comprised a low-risk group of patients was not properly
understood. It was a mistake to extrapolate from its result the
overall population of patients with coronary arteriosclerosis or
even surgical candidates. An example was the editorial that
Braunwald wrote in 1983 (391):
I consider CASS to be an excellent clinical trial and the most
up-to-date examination of the important question of the effects
of CABG on survival and on the occurrence of myocardial
infarction in patients with coronary-artery disease. The lack of
statistical evidence in CASS that survival is improved after
surgical treatment in any patients other than those with disease
of the left main coronary artery. I believe that this operation
should, and increasingly will be, restricted to patients in whom
intensive medical therapy has failed or in whom improved
survival after surgery has been unambiguously demonstrated,
rather than as a panacea for coronary-artery disease.
Nevertheless, he ameliorated his previous strong statement
by posing some questions concerning the effect of CABG:
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(a) Will a statistically significant benefit of the procedure
emerge from a longer follow-up of patients in CASS, particu-
larly those with three-vessel disease? (b) Can survival be
improved significantly by the use of CABG in asymptomatic or
mildly-symptomatic patients with specific anatomic features,
such as the so-called left main equivalent disease or large
fractions of viable myocardium perfused by a single, critically
narrowed coronary artery? (c) Can a subgroup of patients in
CASS be identified, using clinical criteria such as those in the
Veterans Administration trial or a combination of clinical
hemodynamic, and angiographic findings, whose survival is
improved with surgical treatment?
Of the 1,315 patients that refused randomization 570 were
operated on. In another publication the 745 patients that
received only medical treatment were compared with the
former. They reached similar results at six years (392). As a
consequence they concluded “that the data from the random-
izable patients thus support and extend the inference of the
generally very good survival of both the medically and surgi-
cally assigned patients of the randomized trial.”
However, there were significant differences between the
randomized and randomizable patients, as has been empha-
sized by Gunnar and Loeb (393). The randomized surgical
groups had 48.7%, 2.1% and 32.8% of triple-vessel disease, left
main and proximal artery disease respectively. The randomiz-
able surgical group had 62.3%, 9.1% and 46.1%. Therefore we
arrive at the conclusion that patients with different prognoses
have been compared. If we consider that the surgically-
assigned randomizable group was at a significantly high risk,
CABG improved their survival because they reached similar
mortality rate at six years with the medically assigned group
(low-risk population).
Recalling that the original protocol (374) indicated that
refusal to accept randomization was decided by the physician
in 69% of the cases, the following comments of Rahimtoola are
correct: “However, when one examines the therapy adminis-
tered to patients who were not randomized, a difference
becomes evident. Fifty-six percent of patients with disease of
the proximal LAD and 54% of patients with three-vessel
disease who were not randomized underwent CABG. This
contrasts with 33% of patients with two-vessel disease and 31%
of patients with one-vessel disease who were not randomized
and underwent CABG.”
Passamani and collaborators (394) reported actuarial sur-
vival curves for the 106 patients having low ejection fractions.
They conclude that “the data reported support the premise
that elective surgical therapy in patients with triple-vessel
disease and moderately impaired ventricular function confers a
substantial survival benefit at seven years, in addition to the
widely recognized relief of angina.”
In 1984 CASS published the data on myocardial infarction
related to the randomized trial (386). Perioperative myocardial
infarction occurred in 6% of 357 surgical patients. It was 3% in
patients with one-vessel disease, 6% in those with two-vessel
disease and 8% in those with three-vessel disease. The six-year
cumulative probability of remaining alive and free of myocar-
dial infarction was similar in the medical and surgical groups
(79% vs. 80%). Nevertheless, patients with three-vessel disease
showed a probability of remaining alive and free of nonfatal
myocardial infarction slightly better in surgically assigned
patients (88% vs. 80% for the medically assigned group). The
difference was greater for patients with an ejection fraction less
than 0.50 (88% vs. 74% in surgically and medically assigned
groups, respectively).
Certainly, perioperative myocardial infarction plays a sig-
nificant role. I consider that the incidence was high in this
particular group of low-risk patients. Another report from the
CASS registry (395) showed that in 9,777 patients operated on
between 1974 and 1979—2,012 were in angina class IV
(20.5%), 3,934 had unstable angina (40.2%), and 4,648 had
triple-vessel disease (47.5%)—the incidence of perioperative
myocardial infarction decreased from 6.6% in 1974 to 4.1% by
1979. In 1987 another contribution from CASS (396) carefully
documented by mathematical analysis (Cox model with 51
variables and propensity score) 413 medical patients who were
analyzed and compared with 443 surgically treated patients, all
with class I and II angina and triple-vessel disease, and showed
that the possibility of lowering the risk of future myocardial
infarction by surgery required at least two proximal severe
obstructions (72% vs. 92% free of new myocardial infarction in
the medically vs. surgically treated group). The possibility of
benefit also varied with the status of left ventricular function
and was greater in patients with mild and moderate left
ventricle impairment (77% vs. 92% and 74% vs. 88%, respec-
tively). Early surgery was the strongest independent predictor
of freedom from new myocardial infarction.
In 1980 Mason and collaborators (397), after extensive
evaluation of the literature that revealed eight institutions with
satisfactory data in 2,224 patients, reached the following
conclusion: “properly performed coronary bypass grafting is
more effective than modern medical therapy in reducing both
the incidence and the fatal outcome of subsequent acute
myocardial infarction (AMI) in patients with stable angina”
(Fig. 3).
Figure 3. Annual incidence of total and fatal myocardial infarctions
(MI) in surgically treated versus medically treated patients with stable
angina. CABG 5 coronary artery bypass graft surgery; MED. R 5
medical regimen. Data from Mason et al. (397).
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Another important contribution from the CASS registry, by
Holmes and collaborators (398), compared 6,260 medically
treated patients with 7,216 surgically treated patients. They
demonstrated that coronary bypass surgery diminished the
incidence of sudden death at a mean follow-up of 4.6 years
(1.8% of surgically treated patients vs. 5.2% of medically
treated patients). In triple-vessel disease the difference was
even greater (2.7% vs. 14%).
This CASS contribution corroborates what we found in
1977 (316,399) in 206 surgically treated patients and 196
medically treated patients; the incidence of sudden death at 40
months was 1.4% in the surgically treated group vs. 11.2% in
the medically treated group. The great majority of sudden
deaths in the medically treated group occurred in patients with
two and three-vessel disease. The same conclusion was reached
by Vismara and collaborators the same year (309).
Limitations of the randomized trials have been analyzed by
Califf et al. (400) in an editorial in 1986. After describing
significant weaknesses they advise that clinicians should eval-
uate reports from nonrandomized studies, other scientific
observations and personal experience in their own institution,
in addition to the evidence from randomized trials. To cite an
example (Table 4), they presented, from Duke data base, two
patients with three-vessel disease and a rest ejection fraction
.50%:
Patient 1 is a 64-year-old man with frequent exertional
angina, peripheral vascular disease, a previous inferior infarc-
tion, resting ST segment depression, a resting ejection fraction
of 51%, and a 95% stenosis of the proximal left anterior
descending artery. Patient 2 is a 51-year-old man with one
episode of angina per week, no peripheral vascular disease, no
previous infarction, a normal electrocardiography, a resting
ejection fraction of 64%, and 75% distal left anterior descend-
ing lesion. The difference in survival with medical therapy is
dramatic and the predicted benefit from surgery is quite
different between the two patients.
These estimated probabilities of survival were based on statis-
tical models developed from the entire population of patients.
In my opinion, randomized trials, particularly CASS, pro-
duced more confusion than clarification. The high crossover
rate, mainly among patients with triple-vessel disease, with the
intention-to-treat policy, obscured the true results; crossovers
should be considered therapeutic failures if we want to com-
pare different treatments. However, several publications, in-
cluding some from the CASS Registry (44,45,398,401–410),
confirm that CABG, when properly indicated, definitely im-
proves survival in the majority of patients with severe coronary
artery disease. Diminution of sudden deaths and rate of
myocardial infarction were realities that could not be denied.
Even though the surgical population included progressively
more patients at high risk, improvement in surgical technique
allowed us to perform operations with low operative mortality
and morbidity, including patients of advanced age (409,411–
416), and significant deterioration of the left ventricle or
function (410,417–423).
The results in 5,809 patients receiving medical or surgical
therapy analyzed by the Cox proportional hazard regression
model and Kaplan-Meier survival estimation at Duke Univer-
sity (424) (Fig. 4) is a clear example of the evolution of the
results of CABG surgical attempts. The higher the risk, the
more the patients gain from surgery, even after accounting for
the increased surgical mortality.
In 1994 Yusuf and collaborators (425) published an over-
view of 10-year results from randomized trials in patients with
stable angina. Besides the three largest contributions (VA,
European and CASS) they added another four that included
small numbers of patients. Altogether they compared 1,324
patients assigned to CABG surgery and 1,325 patients to
medical management between 1972 and 1984. A detailed
protocol was developed with the aim of obtaining data on every
patient. The statistical method (Kaplan-Meier calculations,
odds ratio for mortality, study interaction by chi-square tests,
logistic regression analysis, restricted means analysis) was
focused on mortality. The patients’ mean age was 50.8. No
angina was found in 11.2% of the population; in the others
angina was class I or II in 53.8% and class III and IV in 35%.
Only 19.7% of patients were judged to have abnormal ejection
fractions and 10.2% had one-vessel disease, 32.4% two-vessel
disease, 50.6% three-vessel disease and 6.6% left main artery
disease. The proximal anterior descending artery was affected
in 59.4%. The operative mortality was 3.2%.
Table 4. Predicted Survival Rate for Two Patients With Left
Ventricular Ejection Fraction .50% and Three-Vessel Disease*
Patient 1 Patient 2
Medical
Therapy
Surgical
Treatment
Medical
Therapy
Surgical
Treatment
1 yr 82% 94% 98% 98%
3 yr 58% 88% 95% 98%
5 yr 42% 82% 92% 97%
*Data from Califf et al. (400).
Figure 4. Comparison of medical and surgical average hazard ratios
for patients treated in 1970, 1977 and 1984 according to coronary
anatomy. Diamonds 5 point estimates; horizontal bars 5 95%
confidence limits of average hazard ratios. Data from Califf et al. (424).
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If we concentrate our analysis on the three largest random-
ized trials (Fig. 5), we will observe that the surgical group had
a better prognosis at five, seven and ten years.
There was a significant risk reduction with CABG at five
years (39%), seven years (32%) and ten years (17%). For
patients with left main artery disease (VA and European) the
mortality reduction was 68% at five years and 33% at 10 years.
Mortality was also significantly lower with CABG in patients
with three-vessel disease at five years (42%) and ten years
(24%). There was a nonsignificant trend toward lower mortal-
ity in patients with single- or double-vessel disease at five years,
but no apparent difference at ten years. Nevertheless, all
patients with proximal left anterior descending stenosis bene-
fited from CABG. Among patients without disease of the
proximal left anterior descending artery significant reduction
was seen only in patients with triple-vessel disease. During
follow-up the difference in mortality narrowed but remained
significant. Overall 37.4% assigned to medical treatment
crossed over to surgery (25% at five years, 33% at seven years
and 41% at 10 years). The crossover rate was higher for
patients with left main artery disease (65% at 10 years) and
three-vessel disease (48%). It is worthwhile mentioning that
66.1% of the medical group were taking beta blockers. Follow-
ing the VA criteria, patients at high risk obtained greater
benefit than patients at low risk. There was a trend toward a
greater benefit from surgery in those with an abnormal exercise
test.
The conclusion of this meta-analysis was that
The overview showed that a policy of routine early CABG
surgery improves survival over a policy of initial medical
therapy (with delayed surgery for advanced symptoms). The
benefits are especially pronounced in patients with more exten-
sive coronary disease or ischemia and in those who have clinical
or angiographic features indicating high or moderate risk.
However, in patients at low risk of death (about a third of the
patients in this data set) the effect on survival was small and the
data were insufficient to indicate whether lives were prolonged
or shortened.
The Introduction of PTCA
On September 16, 1977, Andreas Gruentzig performed the
first coronary angioplasty (426). Since then, thousands of
patients have been clearly benefited by this procedure. In 1983
about 32,300 PTCAs were done in U.S.A. Three years later the
number had increased to 159,643; in 1990 it increased to
300,000; and in 1995 it increased to 400,000 (884,000 world-
wide) (427).
At present PTCA can be performed with low morbidity and
mortality. Death occurs in ;1% or less and the rate of major
complications (death, myocardial infarction and emergency
coronary bypass surgery) is usually between 3% and 5%
(428–442). Certainly the results improve with time and expe-
rience, as clearly demonstrated by the analysis of the NHLBI
PTCA Registry (434). The angiographic outcome and in-
hospital untoward event rate demonstrate that the number of
patients with one or more lesions reduced by .20% and with
residual stenosis ,50% and no death, myocardial infarction or
CABG increase from 55.5% in the first cohort (1977 to 1981)
to 75.1% in the second cohort (1985 to 1986). The improve-
ment in angioplastic intervention increased the percentage of
event-free survival on late follow-up, accompanied by signifi-
cantly better clinical outcome (435,443).
Initially, PTCA was applied mainly in patients with single-
vessel disease. Even in 1988 and 1989, an analysis from a
private insurance data base (444) showed that, at community
level, 96% of procedures were performed on patients with
one-vessel disease. In recent years multivessel angioplasty
increased steadily, especially at leading interventional cardiol-
ogy centers. It is widely accepted that PTCA should be the
treatment of choice among patients with single-vessel disease
even though there are not sufficient data to prove that it
increases life expectancy (445–454). Relief of angina and
better quality of life undoubtedly improve in the angioplastic
population (449,455).
I would like to point out that we must be very cautious in
matching patients with single-vessel disease for analysis of
different treatments. As we will discuss later, the location of
the obstruction, the size of the artery, the distal runoff and
collateral circulation must be carefully observed. Single-vessel
disease is not a uniform group of patients or entity. In our
Figure 5. Mortality rate at 5 (A), 7 (B) and 10 years (C). Dark bars 5
coronary artery bypass graft surgery (CABG); open bars 5 medical
therapy (MT). CASS 5 Coronary Artery Surgery Study; Eur 5
European study; Va 5 Veterans Administration Cooperative study.
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series of 703 acute and subacute myocardial infarctions oper-
ated on between 1971 and 1986, 12 of 45 patients operated due
to severe intractable mitral insufficiency had single-vessel
disease (eight right coronary and four circumflex artery occlu-
sion), and 18 of 56 patients operated due to ventricular septal
defect also had single-vessel disease (nine right coronary, five
anterior descending, and four circumflex artery occlusion). Of
course, all had large vessels (dominant coronary circulation)
and collaterals were absent.
As mentioned previously, with increased experience angio-
plasty was applied to patients with multivessel disease. Only
25% were included in the first NHLBI Registry; the percent-
age increased to 53% in the second registry. This was the result
of important contributions that started at the Mid America
Heart Institute where Hartzler and collaborators were advo-
cating a more aggressive application of interventional cardiol-
ogy (456,457).
Innumerable contributions comparing PTCA with CABG
appear in the literature in the 1980s. Comparison of different
populations made the interpretations difficult. For example,
Finci and collaborators tried to demonstrate that patients
revascularized with both internal mammary arteries obtained
superior results in comparison to multivessel coronary angio-
plasty. The series were incompatible: triple-vessel disease was
present in 20% and 61% of the PTCA and CABG populations,
respectively (458). McCallister and collaborators from the Mid
America Heart Institute (459) compared PTCA to CABG in
patients with multivessel disease. The prevalence of triple-
vessel disease was 47% and 88%, respectively, in the two
groups. The disparity was even greater in the series analyzed by
Akins and collaborators (460): triple-vessel disease comprised
75% of the surgical group versus 6% of the angioplasty group.
Very seldom is the location of the obstruction clearly
specified. We really do not know how many of the lesions
dilated were in proximal segments. If we analyze the contribu-
tion of Teirstein and collaborators (461) from the Mid Amer-
ica Heart Institute, left main equivalent lesion (obstruction at
the proximal segment of the left anterior descending and
circumflex branches of the left coronary artery) comprised only
45 patients (1.45%) of the 3,100 reported between 1981 and
1985 (461). Complete revascularization (both obstructions)
was accomplished only in 64% of the patients, emergency
CABG was required in 5 patients (11%) with 2 deaths (4.4%)
and event-free survival at 22 6 7 months was 89% only among
patients in whom complete revascularization was performed.
Of 5,000 consecutive angioplasties performed in the same
hospital only 275 patients had dilation within each of the three
major coronary arteries or their branches as a single procedure
(462).
Analysis of the status of the left ventricle in most of the
publications divided the angioplastic group by ejection fraction
above and below 0.40 or 0.45. This does not appropriately
analyze patients with a more severe reduction of ejection
fraction.
As an example Myler and collaborators (463) classified 533
patients treated by angioplasty in the following way: 425
patients (79.7%) had an ejection fraction of at least 0.45, in 73
patients (13.7%) the ejection fraction was between 0.44 and
0.35, in 18 patients (3.4%) between 0.34 and 0.25 and in 17
patients (3.2%) below 0.25. Then we know that only 3.2% were
patients with severe left ventricular deterioration. It is very
difficult to compare different treatments if the left ventricular
function is not classified into normal and mild, moderate and
severe.
The literature available in the 1980s demonstrates that in
certain anatomical locations the results of angioplasty were
poor because of a low patency rate, a higher complication rate
and a significant increase of reocclusion within six months:
1. Right coronary artery ostial lesion (464): with 79%
primary success, 9.4% emergency CABG and 38% repeat
PTCA.
2. Proximal left anterior descending (465–468): mainly
because of lower primary success and the high rate of acute
closure and restenosis. For instance, the decline in left anterior
descending angioplasty at Emory University from 70% (1981
to 1982) to 56% (1983 to 1984) might be due to the limitation
of angioplasty for proximal left anterior descending lesions
(469).
3. Total occlusion (470–477): success rate is acceptable if
the occlusion is less than one week in duration (74%) but it
significantly decreases as time passes (between 55 and 65%).
The longer the period that elapses the worse the results (even
lower than 30%). In addition, restenosis rate increases signif-
icantly: between 38 and 48%.
4. Segmental stenosis: although sometimes the initial suc-
cess is gratifying in stenoses greater than 10mm (89%), the
incidence of emergency CABG (3%) and myocardial infarc-
tion (8%) clearly indicates that the results were not compara-
ble to those of localized obstruction (478) and the recurrence
rate increases with the length of the obstruction (479).
5. Multilesion in a single coronary branch: when more than
one obstruction is present in one vessel (467,480–482) primary
success is lower and the restenosis rate is higher (up to 50%).
It is well known that the risk increases if the obstruction is
eccentric, calcified, located at a branch point or near a
tortuosity with an angle $45° (lesion on a bend) (483).
Undoubtedly, restenosis is the most important problem
related to angioplasty, documented since the early Zurich
experience by Gruentzig (484). In a study carried out at Emory
University the arteriograms of 82 patients (107 lesions) were
analyzed using electronic calipers (485) within 48 hours 10% of
the asymptomatic successful PTCA showed restenosis but
some of them improved during the healing phase. These
results were confirmed by a contribution from Japan (486): at
24 hours 9% of the patients already showed clear evidence of
restenosis. Rodriguez and collaborators (487) also confirmed
this finding. A repeat catheterization at 24 hours demonstrated
that 23% had early loss of luminal diameter. This group of
patients had a significant restenosis rate at six months.
Furthermore, the utilization of early assessment by dipyr-
idamole, thallium-201 single photon computed tomography in
40 patients (mean 1.9 days) demonstrated reversible perfusion
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defects in 35%. In this group catheterization performed at a
mean follow-up of 5.2 months showed 57% restenosis (488).
Most believe that in approximately 20% to 30% of success-
ful angioplasties, restenosis may be recognized within 6
months. However, reviewing several contributions (466 –
468,471,472,475,477,480–482,489–504) yields the impression
that the restenosis rate is higher because, although symptom-
atic patients are restudied more often, it has been found that
between 19 and 28% of the asymptomatic patients also showed
restenosis of previously successful PTCA. Therefore, absence
of angina is not a reliable index of patency. As pointed out by
Myler and Shaw (501) the percentage can be presented in
different ways: in their series of 470 patients of multiple PTCA,
286 were followed during 6 months and only 164 had repeat
catheterization, 92 of whom showed restenosis. The percent-
age can be calculated as follows: 92 of 164 5 56%; 92 of 286 5
32%; 92 of 470 5 20%. They believe 32% is much more
realistic than 56% or 20%. Their approach to the problem is
indeed open to discussion. Only repeat catheterization in
consecutive patients will give us realistic numbers and the
percentage in such reports varies between 32% and 40%.
Furthermore, in patients with multivessel disease the recur-
rence rate is higher and appears to be cumulative. Patients with
diabetes, smoking, shorter angina duration and prior myocar-
dial infarction are more prone to develop restenosis. Balloon
size, higher balloon inflation pressure, difficulty in crossing the
stenosis, more than one dilation, higher diameter stenosis pre
PTCA, higher residual stenosis post PTCA, residual translu-
minal pressure gradient, presence of a clot, characteristics of
the distal flow and location of the obstruction increase the
percentage of restenosis.
Several pharmacological approaches, including heparin,
aspirin, dipyridamole, ticlopidine, nifedipine, prostacyclin and
steroids, failed to decrease the rate of restenosis (505–513). At
present, there are new promising approaches, mainly through
molecular biology. An excellent summary may be found in a
recent publication by Spencer King (514).
New devices (515) have expanded the indications for in-
traluminal treatment, mainly in overcoming some of the limi-
tations of balloon angioplasty. They have been the subject of
considerable debate since 1990 (516–524). The concept of
atherectomy (atheroma removal) was introduced by John
Simpson (525,526). It has gone through a period of major
enthusiasm, followed by a reduction in its use after the result of
two randomized trials, CAVEAT (527) and CCAT (528), in
which no clear advantage could be seen. Nevertheless there are
some kinds of lesions, not tested against other devices, where
atherectomy still seems to have a role: LAD-origin lesions,
ostial lesions, severely eccentric lesions and bifurcation lesions
(529).
High speed rotational atherectomy developed by Hansen
and Auth (530) is a procedure that has proven to be especially
effective where complex lesion characteristics such as calcifi-
cation, tortuosity, small caliber, ostial location and diffuse
disease typically increase the risk of intervention with conven-
tional catheters (531). Restenosis rates are comparable to
balloon angioplasty in the randomized ERBAC trial (532).
The transluminal extraction catheter (TEC) or extraction
atherectomy (533) is a percutaneous, over the wire, motor
driven, cutting and aspiration system. The distal cutting tip has
a conical configuration consisting of two stainless steel blades
with adjacent windows. It is a device adapted with vacuum
capability to treatment and removal of thrombi and also
indicated for saphenous vein graft lesions. As a limitation it has
a relatively high incidence of myocardial infarction due to
distal embolization of plaque.
In two trials, the AMRO trial (534,535) and the ERBAC
trial (532) the excimer laser was tested against balloon angio-
plasty and Rotablator; it did not show any advantage over
conventional percutaneous balloon angioplasty.
The principal limitations of balloon angioplasty, coronary
occlusion and restenosis, have been reduced with the utiliza-
tion of stents, from 42.1% to 31.6% in the STRESS study (536)
and from 32% to 22% in the BENESTENT group (537). But
in stented vessels ,2.6 mm in diameter, the 6-month restenosis
rate was 38% compared with 22% in vessels .3.4 mm (538). In
both randomized trials, the acute gain in luminal diameter was
greater for stents than for balloons but at six months there was
a greater late loss for stents than for balloons (0.65 vs. 0.32 in
BENESTENT and 0.74 vs. 0.38 in STRESS). Long-term
studies are necessary. Topol (539) pointed out that “tens of
thousands of patients are receiving a prosthetic metal device in
their coronary arteries without adequate long-term follow-up,
and most of these patients are receiving it for indications that
have not been systematically or rigorously evaluated”. Never-
theless, at present, between 40% and 60% of the patients sent
for angioplasty are getting one or more stents. It is important
to remember that this therapy is indeed very expensive,
average laboratory cost in the STRESS trial was approximately
$ 3,200 more than PTCA (540).
Nowadays more than twenty designs of stents have been
implanted in patients, with an added risk of complications due
to the anticoagulation regime. Nevertheless, with intracoro-
nary ultrasound guidance, Colombo showed the safety of stent
deployment with high pressure balloon inflation, avoiding the
oral anticoagulation with consequent reduction of the vascular
complications and reduced hospital stay (541). This strategy
may facilitate the expanded use of stents to provide the benefit
of decreased restenosis while simultaneously reducing the cost
and complications associated with stent insertion.
Lastly, recent advances in the intravascular ultrasound
imaging technique have enabled visualization of the intralumi-
nal and intramural morphology of the coronary arteries, a
helpful technique in improving proper indications (542–546).
The introduction of new developments—such as the cath-
eter, which can deliver beta radiation to prevent restenosis—
seems to be promising (547,548). The search for the ideal stent
continues. Areas of intense interest such as the polymer stent
loaded with antithrombotic or antiproliferative agents, the
exciting concepts of stents made of materials that can be
degraded or absorbed and the promising new field of the
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radioactive stent may expand the use of stents in the hope of
reducing restenosis, the Achilles’ heel of PTCA.
The Randomized Trials: PTCA Versus CABG
As a consequence of the dissenting opinions about patients
with multivessel disease randomized trials were required. In
one of his last contributions Andreas Gruentzig (484) said,
“Patients with single-vessel disease treated with angioplasty
seem to have passed the test of time; however, patients with a
more complex multivessel disease present more difficult prob-
lems in the follow-up period. Randomized trials now under
way will help to determine the value of angioplasty in patients
with multivessel disease.”*
My analysis will concentrate on five trials: Coronary Angio-
plasty versus Bypass Revascularization Investigation (CABRI),
Randomized Intervention Treatment of Angina (RITA) Trial,
Emory Angioplasty versus Surgery Trial (EAST), German
Angioplasty Bypass Surgery Investigation (GABI) and Bypass
Angioplasty Revascularization Investigation (BARI). They
comprise the largest populations recruited from 1986 to 1992.
The data in Table 5 allow comparison between 2,346 patients
belonging to the PTCA group and 2,299 of the CABG group
(549–553).
In Table 6 the baseline characteristics of the population
demonstrate that, except for the RITA trial, all of them were
restricted to patients with double- and triple-vessel disease.
RITA and GABI included a small number of patients with
triple-vessel disease. In fact, RITA should be considered a
double- and single-vessel disease trial and GABI, a double-
vessel disease trial. Patients with unstable angina were ac-
cepted in BARI, RITA and GABI.
Patients were included in RITA, GABI and BARI only
when surgeons and cardiologists agreed that both procedures
could be applied. As we will discuss later, this approach
introduces a significant bias in the selection process. Patients
with severe triple-vessel disease—though not explicitly speci-
fied—were excluded from CABRI. In EAST the eligibility
criteria were confusing: “the clinical criteria for exclusion were
insufficient myocardium at risk to warrant surgery (318 pa-
tients).” The principal angiographic criteria for exclusion
“were old (more than eight weeks’ duration) chronic occlusion
of bypassable vessels serving viable myocardium” and “two or
more total occlusions.” Triple-vessel disease with multiple
lesions comprise only 27% and 26% in the PTCA and CABG
group (554). Patients with left main coronary obstruction were
excluded from all five trials.
Table 7 demonstrates that the in-hospital death rate of the
five trials was slightly higher in CABG than in PTCA patients
(1.8% vs. 1.5%, odds ratio [OR] 1.17). The combined risk of
death and nonfatal myocardial infarction was also higher in
CABG than in PTCA patients (7.6% vs. 4.6%, OR 1.67).
*The EAST Trial was first conceived by Andreas Gruentzig.
Table 5. Population Included in Five Randomized Trials
Trial and Location Single or Multi-VD
CABG
(no. of pts)
PTCA
(no. of pts)
Duration of
Follow-Up (yr)
CABRI
Europe Multi-VD 513 541 1
RITA
UK Single-VD (n 5 456) and
Multi-VD (n 5 555)
501 510 4.7
EAST
USA Multi-VD 194 198 3
GABI
Germany Multi-VD 177 182 1
BARI
USA and Canada Multi-VD 914 915 5
Total: 2,299 2,346
BARI 5 Bypass Angioplasty Revascularization Investigation; CABRI 5 Coronary Angioplasty Versus Bypass
Revascularization Investigation; EAST 5 Emory Angioplasty Versus Surgery Trial; GABI 5 German Angioplasty Bypass
Surgery Investigation; PTCA 5 percutaneous transluminal coronary angioplasty; RITA 5 Randomized Intervention
Treatment of Angina Trial; VD 5 vessel disease; other abbreviations as in Tables 1 and 2.
Table 6. Description of Study Populations of Five Clinical Trials
BARI RITA CABRI GABI EAST
Men 74% 81% 78% 80% 74%
Mean age (yr) 61 57 60 59 62
Mean LVEF 57% — 63% 56% 61%
Prior MI 54% 42% 42% 47% 41%
Angina
CCS class 0–II 14% 41% 34% 35% 20%
CCS class III–IV 17% 59% 66% 65% 77%
Unstable 64% 55% — 14% —
No. of coronary
arteries narrowed
1 2%* 45% 0 0 0
2 57%* 43% 60% 82% 60%
3 41%* 12% 40% 18% 40%
*Diseased territory .50%. Data presented are percent of patients or mean
age. Abbreviations as in Tables 2 and 5.
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Within one year (Table 8) death and myocardial infarction
remained higher in CABG (10.4% vs. 8.7%, OR 1.20). At
three years the rate was slightly higher among PTCA patients
(12.8% vs. 11.3%, OR 0.89). At five years, the BARI trial also
showed a slightly higher rate among PTCA patients (21.3% vs.
19.6%, OR 1.00). During the first year (Table 9) PTCA
patients required additional procedures (PTCA 1 CABG)
(43.9% vs. 4.1%, OR 0.9). This rate increased within three
years (62.6% vs. 8.3%, OR 0.13) in RITA, EAST and BARI
trials. The difference was slightly greater at five years for the
BARI trial (63% vs. 8%, OR 0.13). In Table 10 it is clear that
patients treated with CABG were significantly more likely to
be angina free.
The conclusions of the five trials can be summarized as
follows: in patients with multivessel disease a strategy of initial
PTCA compared to a strategy of initial coronary artery bypass
did not differ with respect to the occurrence of primary end
point: death and myocardial infarction during hospitalization
and midterm follow-up. However, a clear difference existed
between the two treatment policies in terms of the require-
ments for additional revascularization procedures and relief of
symptoms. CABG involved longer initial hospitalization and
convalescence, but thereafter surgically treated patients en-
joyed better relief of angina and required fewer antianginal
drugs.
Are these conclusions representative of a carefully docu-
mented analysis? Let us concentrate on BARI, which com-
prises the largest number of patients in a single trial.
On March 23, 1995, the American Journal of Cardiology
released a supplement that included four contributions with
BARI baseline features. The first (555) included the patients
screened (Fig. 6). From 12,530 “clinically eligible” patients 915
were finally randomized to PTCA and 914 to CABG. As
planned by the original protocol, the final determination of
eligibility involved the subjective judgment of both the angio-
plasty operator and the surgeon, but in most settings exclusions
were made primarily by the angioplasty operator (90%) (Table
Table 8. Follow-up Results: Cardiac Death and Myocardial Infarction
CABG
(% of pts)
PTCA
(% of pts)
Odds
Ratio
During 1st yr
RITA 6.20 6.70 0.93
CABRI 5.70 7.90 0.72
GABI 10.20 5.50 1.85
EAST 18.40 13.70 1.34
BARI 11.70 9.80 0.84
Average 10.40 8.70 1.20
During 1- to 3-yr follow-up
RITA 8.90 10.10 0.88
CABRI 5.70 7.90 0.71
GABI 0.60 2.20 0.26
EAST 27.00 28.80 0.94
BARI 14.40 14.80 0.98
Average 11.30 12.80 0.89
At 5 yr
BARI 19.60 21.30 1.00
Abbreviations as in Tables 1, 2 and 5.
Table 7. In-Hospital Results
CABG
(% of pts)
PTCA
(% of pts)
Odds
Ratio
Death
RITA 3.60 3.10 1.15
CABRI 0.70 1.30 0.54
GABI 2.30 1.10 2.06
EAST 1.03 1.01 1.02
BARI 1.30 1.10 1.20
Average 1.80 1.50 1.17
Death1nonfatal MI
RITA 8.80 9.80 0.90
CABRI 2.70 2.80 0.98
GABI 9.60 3.30 2.91
EAST 11.30 4.00 2.81
BARI 5.70 3.00 1.93
Average 7.60 4.60 1.67
Abbreviations as in Tables 1, 2 and 5.
Table 9. Follow-Up Results: Additional Interventions (PTCA
and/or CABG)
CABG
(% of pts)
PTCA
(% of pts)
Odds
Ratio
During 1st yr
RITA 4.8 40.8 0.12
CABRI 2.9 35.9 0.08
GABI 7.3 45.6 0.16
EAST 3.1 50.0 0.06
BARI 2.5 47.0 0.05
Average 4.1 43.9 0.09
At 3 yr
RITA 6.0 68.6 0.09
EAST 13.9 63.1 0.22
BARI 5.0 56.1 0.09
Average 8.3 62.6 0.13
At 5 yr
BARI 8.00 63.0 0.13
Abbreviations as in Tables 1, 2 and 5.
Table 10. Follow-Up Results: Prevalence of CCS Class II or
Worse Angina
CABG
(% of pts)
PTCA
(% of pts)
Odds
Ratio
At 1 yr
RITA 10.60 20.60 0.52
CABRI 11.00 15.60 0.70
GABI 25.20 28.40 0.89
EAST 9.00 18.50 0.49
Average 13.90 20.80 0.67
At 3 yr
RITA 16.00 18.10 0.88
EAST 11.20 19.00 0.59
Average 13.60 18.60 0.73
Abbreviations as in Tables 1, 2 and 5.
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11). In 49.8% of patients excluded by the angioplasty operator,
CABG was indicated. On the contrary, among patients ex-
cluded by the surgeon only in 1.4% was PTCA done or
intended.
The reasons for angiographic exclusion among those judged
unsuitable were: total occlusion, predominantly diffuse disease
and excessive length, angulation, calcium and tortuosity, and,
among those judged dangerous, were: the potential for abrupt
closure leading to shock and impossibility of protection of side
branches, in addition to other reasons.
They concluded: “It is clear from the angiographically
excluded data that patients with the most complex coronary
artery disease were treated, as a rule, with CABG. Thus, the
BARI randomized and eligible but not randomized cohorts
represent that portion of patients with multivessel coronary
artery disease whose coronary anatomy allows the option of
either procedure and who present for revascularization with
less complex lesion morphology.”
The second paper (556) analyzed the baseline clinical and
angiographic data. The analysis of the randomized patients
(Table 12) demonstrated similar characteristics. The percent-
age of proximal left anterior descending lesions was similar to
the CASS randomized population and was half that of the
European study. The analysis of Table 13 showed that
The angiographically excluded group, as expected, had
more extensive coronary artery disease on angiography as was
evident from more three-vessel disease, more type C lesions,
more total occlusions, more proximal stenoses, lower ejection
fractions, and more jeopardized myocardium than the random-
ized or eligible but nonrandomized groups. Further analysis of
a second registry of patients ineligible for randomization due to
coronary anatomy unsuitable for either PTCA or CABG dem-
onstrated that such patients were older, had more prior myo-
cardial infarctions, heart failure and stable angina presentation.
Regarding the angiographically excluded patients “in view
of their advanced age, stable anginal pattern, severe coronary
disease, and worse left ventricular function, it is not surprising
that, at 3 months follow-up, many (33%) were still being
managed with medical therapy, very few (5%) had undergone
PTCA, and the remainder (60%) had received CABG.” They
conclude that: “although the BARI randomized population
seems representative of the universe of patients meeting the
BARI entry criteria at the participating centers, it is not
representative of all patients with multivessel coronary artery
disease who have clinical indications for revascularization,
because many such patients do not qualify for both PTCA and
CABG.”
Figure 6. Number of inclusions and exclusions in Bypass
Angioplasty Revascularization Investigation (BARI) re-
cruitment. CABG 5 coronary artery bypass graft surgery;
PTCA 5 percutaneous transluminal coronary angio-
plasty; Rand. 5 randomization. Data from Bourassa et al.
(555).
Table 11. Angiographic Exclusions and Treatment Received or
Intended as of Hospital Discharge (8,420 patients)
Therapy Received
or Intended
PTCA Only
(n 5 7,576)
CABG Only
(n 5 420)
PTCA and CABG
(n 5 424)
PTCA
Received 83 101 17
Intended 54 96 10
CABG
Received 1,091 1 4
Intended 2,680 5 9
Medical treatment
Received 1,288 142 315
Intended 2,380 75 69
Data presented are number of patients. Abbreviations as in Tables 1 and 5.
Table 12. Baseline Characteristics of BARI Trial
Randomized Patients
PTCA
(% of pts)
CABG
(% of pts)
Proximal stenoses
Proximal LAD stenosis $50% 36 37
Proximal or mid-LAD stenosis $50% 77 76
Any proximal stenosis $50% 68 68
Dominance
Right 80 81
Left 7 6
Mixed 13 13
*Data from Rogers et al. (556). BARI 5 Bypass Angioplasty Revasculariza-
tion Investigation; other abbreviations as in Tables 1, 2, 3 and 5.
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The third paper (557) concentrated on the procedural
characteristics of patients randomized to coronary angioplasty:
There were 6,530 coronary arterial lesions identified in the
915 patients assigned to angioplasty. Angiographically signifi-
cant ($50% diameter reduction) lesions accounted for 52.5%
of all lesions. Angiographically significant lesions within the left
anterior descending, left circumflex, or right coronary arteries
were usually located in either the proximal (40.8%) or mid
(44.8%) segments. Total occlusions accounted for 11.9% of
angiographically significant lesions. The lesions most frequently
attempted ranged between 50% and 79% diameter reduction.
This group is followed by those in the 50–59% and 80–89%
ranges. Lesions ,49% and those .90% were less frequently
attempted. In contrast, only 30.1% of lesions classified as
99–100% were attempted.
The way the data are presented in this contribution is
potentially confusing. Table 1 from this paper is a clear
example. Critical analysis demonstrated that only 47.1% of the
lesions greater than 50% were successfully dilated (Table 14).
It is worth mentioning that 393 lesions with 99% obstruction
and 53 total occlusions were attempted with a 23.8% successful
rate.
Analysis of the EAST, CABRI, RITA and GABI trials
showed success rates of 54%, 60%, 61% and 79% for PTCA,
respectively, for the total number of obstructions.
An important question is whether the significant rate of
repeat PTCA and CABG in the angioplasty group is a conse-
quence of restenosis or initial incomplete revascularization.
Since the NHLBI early contribution (558) we know that
incomplete revascularization increases the number of new
interventions.
The fourth paper (559) analyzed the characteristics of
patients randomized to bypass surgery. They conclude that
“indeed, 60% of clinically eligible patients were judged unsuit-
able for PTCA but were suitable for CABG. Clearly, choosing
patients with multivessel involvement based on their suitability
for PTCA selects patients with less advanced coronary athero-
sclerosis. Approximately only 33% of patients with multivessel
disease were considered potential candidates for either PTCA
or CABG.”
Detre and collaborators (560) in a recent survey of the
centers that participated in the BARI trial and 75 other
institutions, concluded that approximately 12% of all patients
who required revascularization would be eligible for the BARI
trial.
The subgroup of patients with treated diabetes had better
survival with coronary artery bypass, as shown by the absolute
difference of 16%, and led to a clinical alert release on
September 21, 1995 (561).
Robert Frye, in his presentation of the BARI results
(personal communication) during the annual meeting of the
American Heart Association (November 1995), stated that
BARI was designed to determine the safety of a strategy of
initial PTCA in selected patients with multivessel coronary
artery disease. This finding and the desire of many patients and
doctors to avoid for as long as possible the sternotomy associ-
ated with coronary artery bypass prompts testing the following
question: in patients needing revascularization, can PTCA, a
less invasive strategy, delay or prevent the need for CABG
without adverse consequences? The answer is clearly yes.
I believe that “selected patients with multivessel disease” do
not represent the true picture. Instead they could have been
replaced by only 33% of a selected group of patients with
triple-vessel disease candidates for both PTCA and CABG.
It is worth mentioning that even when complete revascu-
larization is performed with PTCA in patients with multivessel
disease, the results are quite similar to those of the randomized
trials. Vacek and collaborators (562) selected 152 patients
(only 5% of the total PTCA population of the Mid America
Heart Institute) where three or more dilatations in the major
coronary arteries were accomplished, and compared them with
134 patients who had more than three bypass grafts (left
Table 13. BARI Trial: Angiographic Data
Randomized
Eligible, Not
Randomized
Angiographically
Excluded
No. of pts enrolled 1,829 2,013 422
No. of pts with
angiographic
interpretation
available
1,826 1,945 417
VD (50% stenosis
criteria)
Single 2% 2% 2%
Double 57% 61% 38%
Triple 41% 37% 60%
Lesions with stenosis
$50%
Mean 3.5 3.0 4.2
Median no./pt 3 3 4
Proximal stenoses
Proximal LAD
stenosis $50%
37% 35% 47%
Proximal or mid-
LAD stenosis
$50%
77% 69% 80%
Any proximal
stenosis $50%
68% 68% 81%
Total occlusions
Mean 0.4 0.3 1.1
Median no./pt 0 0 1
None 63% 69% 26%
1 31% 28% 41%
2 6% 3% 26%
$3 ,1% ,1% 6%
Type C lesions
Mean 0.5 0.5 1.3
Median no./pt 0 0 1
None 60% 63% 22%
1 32% 31% 39%
2 7% 6% 28%
$3 1% 1% 11%
Data from Rogers et al. (556). Abbreviations as in Tables 2, 3 and 5.
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internal mammary in 75% of the cases). The PTCA group
received an average of three dilatations, the surgical group, 3.9
bypasses. At 110 weeks of follow-up the rate of deaths and
myocardial infarctions were 14% vs 16% in the PTCA and
CABG groups, respectively. But in the PTCA group 49%,
17%, 5% and 3% had 1, 2, 3 or 4 repeat catheterizations.
Thirty percent had a second PTCA and 23% underwent
CABG. In the surgical group only 10% underwent a second
catheterization, 2% had a reoperation, and another 2% a
PTCA. Survival at two years was similar: 91% and 90% for the
PTCA and CABG groups, respectively. The CABG population
had more extensive triple-vessel disease (68% vs 6% on the
PTCA group) a higher percentage of left anterior descending
artery obstructions and lower ejection fraction.
They concluded:
However, our data would suggest that for important cardiac
end points, CABG for multivessel disease, which routinely uses
left internal mammary artery bypass grafts, is a superior inter-
vention when compared with multivessel angioplasty. Proposed
financial savings attributable to angioplasty may also be obvi-
ated by the need for a greater number of repeat studies and
interventions in follow-up. Caution should be exercised in the
widespread application of multivessel PTCA.
As we have seen, a significant number of patients require
further revascularization procedures after the first PTCA. I
have the impression that a careful examination of the cine
coronary angiography of the patients from randomized trials
that required surgery as a second procedure would constitute a
significant contribution. Perhaps some clues could be found for
improvement in the indications for PTCA.
Johnson and collaborators (563) analyzed a group of 256
patients with multivessel disease treated with angioplasty. One
hundred and twenty-eight who had successful PTCA (group A)
required subsequent CABG performed at a mean interval of
16.7 months (22 patients—17.2%—had CABG within 30 days
of initial PTCA). Sixty-five patients (51%) had 92 additional
PTCA before the operation. Of the other 128 patients (group
B) none required CABG, and 24 (18.8%) had a second PTCA
at a mean interval of 11 months. Patients who required
emergency CABG associated with their initial PTCA and those
who had unsuccessful angioplasty were excluded from both
groups.
Clinical characteristics were similar, except that patients
with diabetes comprised 27.3% of group A vs 14.1% in group
B. The analysis of the angiographic characteristics (Table 15)
clearly demonstrates that patients in group A had more
obstruction with increased number of left anterior descending,
circumflex and left main trunk lesions. “Nearly all of the
patients in group A with four or more coronary stenoses $70%
required their operation within one year.” I think this contri-
bution demonstrates that in most of the patients from group A,
PTCA was not the proper indication.
Many years ago I pointed out (316,399) that the single-,
double- and triple-vessel disease classification is not enough if
we want to analyze patients with coronary artery disease
properly and it is inadequate for comparison of different
treatments.
Table 14. Lesions Present, Intended, Attempted and Successful for Angioplasty in BARI
Trial Patients*
No Lesions in Pts
Assigned to PTCA
(n 5 915)
No Lesions With
Intended PTCA
No Lesions With
Attempted PTCA
No Lesions With
Successful PTCA
All lesions 6,530 2,296 2,218 1,681
(35.7%) (33.1%) (26.1%)
50% to 79% total 2,585 1,732 1,612 1,273
(67.8%) (63.1%) (49.8%)
80% to 95% total 396 286 274 216
(73.3%) (70.3%) (55.5%)
99% to 100% total 446† 145 132 104
(33.0%) (30.1%) (23.8%)
Total 3,427 2,163 2,018 1,594
(63.9%) (59.6%) (47.1%)
*Data elaborated from Williams et al. (557). †Total occlusion 11.9%. Abbreviations as in Tables 2 and 5.
Table 15. Location and Severity of Coronary Lesions in the Two
Study Groups*
Lesion Severity and
Location at Initial
PTCA
Group A
(CABG subsequent
to PTCA)
Group B
(no CABG subsequent
to PTCA)
p
Value
Total no. of lesions
(any lesions)
4.1 6 2.2 3.27 6 1.9 0.002
Lesions $70% 2.7 6 1.5 1.97 6 1.2 0.0001
Pts with LAD
$70%
98 (70.6%) 75 (58.6%) 0.002
Pts with Cx $70% 57 (44.5%) 34 (26.6%) 0.006
Pts with RCA
$70%
65 (50.8%) 67 (52.3%) 0.900
Any LMCA stenosis 15 (11.7%) 8 (6.3%) 0.126
LMCA $50% 3 (2.3%) 0 (0%) 0.081
*Data from Johnson et al. (563). Data presented are mean value 6 SD or
number (%) of patients. Abbreviations as in Tables 1 to 3 and 5.
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In 1977 Abedin and Dack (310), and later on Leong et al
(377), Brooks et al (378), and Chaitman et al (379) demon-
strated that the prognosis of patients with obstruction of the
anterior descending coronary artery is related to the site of the
obstruction.
In 1982 Mock and collaborators (564,565) emphasized the
role of the proximal obstruction among patients with multives-
sel disease and in 1983 Ringqvist (566) contributed an excel-
lent paper which indicated (Table 16) that, in addition to the
number of diseased vessels, the location of the obstructions
and the status of the left ventricle defined the future of patients
with coronary artery disease. Survival at six years varied
between 92% and 16%!
Afterward, Myers and collaborators (385,396,567) re-
marked that the number of obstructions is an important
landmark. Fifty-one variables, including therapy, were tested
by Cox model and a propensity score was utilized to compare
medical and surgical treatment. As an example, at six years
significantly longer survival was not found in patients with
severe angina, triple-vessel disease, normal left ventricular
function and one proximal obstruction (87% vs. 91% survival
in the medical and surgical groups respectively). However,
there was improved survival with two proximal obstructions
(73% vs. 89%) and three proximal obstructions (38% vs. 90%).
In patients with triple-vessel disease and mild angina (385)
there was improved survival with two proximal obstructions
(67% vs 89%) and three proximal obstructions (54% vs 84%).
Following Ringqvist’s classification, it would be a good idea
to compare the group of patients included in the five random-
ized trials that underwent CABG after being treated with
PTCA with patients who remained in the PTCA group.
Recently, Jones and collaborators at Duke University (568)
completed a previous report (569) of 9,263 patients (CABG
3,890, PTCA 2,924 and medical treatment 2,449) followed for
a mean interval of 5.3 years. They classified patients into nine
categories (left main trunk obstructions were excluded). Be-
sides single-, double- and triple-vessel disease, they specified
the presence of 75% and 95% obstructions and 75% and 95%
proximal left anterior descending obstructions (Fig. 7). The
analysis clearly demonstrated (Fig. 8 and 9) that CABG
improved survival in relation to the number, severity and
location of the obstruction.
I think this important contribution clearly demonstrates
that the simple classification of single-, double- and triple-
vessel disease is not enough.
The Future
There are two areas of potential increased application of
CABG: (a) asymptomatic patients and (b) AMI.
Asymptomatic Patients
In this category we should differentiate patients who lead a
normal life without any restriction of their physical capacity,
from the group who limit their activities on advice of their
physician. The discussion will concentrate on the first group.
The natural history of coronary arteriosclerosis shows that
the incidence of prodromata among patients suffering a first
myocardial infarction ranges from 15% to 65% (570–579).
Pain has been reported in 27% and 45% and in only one study
was its prevalence 59% (578). On the other hand, half of all
deaths due to coronary arteriosclerosis are sudden (580,581)
and about 50% occur in patients with no previously known
ischemic heart disease (582). It is clear that pain is a late and
luxurious manifestation of coronary arteriosclerosis.
Myocardial ischemia is frequently painless (583–586).
Asymptomatic ischemia is the most common form of myocar-
dial perfusion deficit (587), even in patients who experience
clinical episodes of angina. It is recognized that myocardial
ischemia is an important determinant of mortality and mor-
bidity (587–598) and it is related to the extent of coronary
artery disease and myocardium at risk (401,599–601).
Table 16. Six-Year Survival Rates (61.96) by Number of Vessels
Diseased, Number of Proximal Arterial Segments Diseased and Left
Ventricular Wall Motion Score (number of patients in cell at
enrollment) for the CASS Study*†
No. of Diseased Vessels/
No. of Proximal
Segments Diseased
Left Ventricular Score
5–11 12–16 17–30
Total No.
of Pts
(n 5 8,535)
0/0
6-yr survival 93 6 2% 76 6 13% 78 6 27%
No. of pts 1,836 45 9 1,890
1/0
6-yr survival 92 6 2% 81 6 8% 65 6 20%
No. of pts 1,430 219 36 1,685
1/1
6-yr survival 90 6 3% 76 6 9% 55 6 19%
No. of pts 796 204 65 1,065
2/0
6-yr survival 81 6 6% 49 6 22% 52 6 18%
No. of pts 652 128 37 817
2/1
6-yr survival 86 6 4% 67 6 10% 54 6 14%
No. of pts 617 188 71 876
2/2
6-yr survival 72 6 9% 51 6 14% 43 6 20%
No. of pts 234 102 39 375
3/0
6-yr survival 76 6 10% 53 6 12% 25 6 36%
No. of pts 238 96 29 363
3/1
6-yr survival 74 6 7% 43 6 12% 47 6 13%
No. of pts 371 191 71 633
3/2
6-yr survival 66 6 8% 47 6 9% 24 6 13%
No. of pts 297 165 74 536
3/3
6-yr survival 57 6 13% 29 6 14% 16 6 14%
No. of pts 156 93 46 295
*Data from Rinqvist et al. (566). †Zero includes patients with minimal or
moderate disease; the percentages in relation to the status of the heart muscle
are similar to the randomized series: 5–11 5 77.6%; 12–16 5 16.7%. Data presented
are mean value 6 SD, unless otherwise indicated. Abbreviations as in Table 2.
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There are different ways in which patients with asymptom-
atic coronary arteriosclerosis seek medical advice:
Asymptomatic patients with previous myocardial infarc-
tion. In 1984 we analyzed the data accumulated in 344 patients
studied by cine coronary angiography after only one previous
myocardial infarction (399). In anterior infarction 43% had
multivessel disease and 3% had left main trunk obstruction
(Fig. 10, left). In posterolateral infarction (Fig. 10, right) 55%
had multivessel disease, and 4% had left main trunk obstruc-
tion. We might predict that in patients with only one previous
infarction most should have only one major obstruction, but
this occurs only in 51.8% and 40.8% of anterolateral and
posterolateral infarctions, respectively.
We should add to this group of patients those who have
abnormal electrocardiograms on routine examination, espe-
cially those with evidence of a previous silent myocardial
infarction. The Framingham Study (602) showed that the
prognosis for patients with silent myocardial infarction mani-
fest only electrocardiographically is similar to that for patients
with a clear-cut history of previous myocardial infarction.
Patients with atherosclerotic manifestations in noncoro-
nary vascular beds. Since 1972 in our cardiac laboratory we
have studied all the patients that required visualization of a
particular vascular territory by cine angiography. Coronary
angiography was performed during the same time period as
other investigations (603,604) even though angina was not
present.
As can be seen in Table 17, 84% of the patients demon-
strated different degrees of coronary atherosclerosis including
7% with left main trunk disease. If we analyze the last
consecutive 124 patients (78 with peripheral vascular disease
Figure 8. Adjusted hazard ratios comparing coronary artery bypass
graft surgery (CABG) and medical therapy (MT) for the nine coronary
anatomy groups. LAD 5 left anterior descending coronary artery; N 5
no; Prox 5 proximal; Surv. 5 survival; VD 5 vessel disease; Y 5 yes;
95% 5 95% coronary artery stenosis. Data from Jones et al. (568).
Figure 7. Coronary anatomy score for 6,034 medically treated
patients undergoing coronary angiography at Duke University
Medical Center between 1969 and 1984. The anatomic classi-
fication of coronary artery stenosis is related to the corre-
sponding relative prognostic weight. LAD 5 left anterior
descending coronary artery; N 5 no; Y 5 yes. Data from
Jones et al. (568).
Figure 9. Adjusted hazard ratios comparing coronary artery bypass
graft surgery (CABG) and percutaneous transluminal coronary angio-
plasty (PTCA) for the nine coronary anatomy groups. Other abbrevi-
ations as in Table 8. Data from Jones et al. (568).
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and/or abdominal aorta disease, 40 with cerebrovascular insuf-
ficiency, and 6 with renal artery obstruction) in whom we
studied the coronary arteries even though there was no anginal
episode in their clinical history, we found that 38 patients
(28.3%) had one-vessel disease, 17 patients (14.1%) had
two-vessel disease, 31 patients (25.8%) had three-vessel dis-
ease, 7 patients (6%) had left main trunk obstruction, and 31
(25.8%) had normal coronary arteries.
Patients with a definite family history or the presence of
other risk factors. Such high risk factors mainly include
abnormal lipids, hypertension and diabetes.
Patients with associated valvular disease. First in Cleve-
land and since 1971 in Buenos Aires, most patients with
valvular disease who were candidates for reconstruction or
valvular replacement underwent routine coronary angiography
during catheterization. Patients with aortic or mitral valve
disease could have concomitant severe coronary atherosclero-
sis, even though angina was absent (605).
Patients with positive exercise tests on routine examina-
tion. Review of the literature is confusing and it is difficult to
draw definite conclusions mainly because the majority of the
publications are based on a small number of patients or
because there is not a clear analysis of the correlation with the
cine coronary angiography (337,606–626). In patients with a
positive exercise test the probability of detecting coronary
atherosclerosis is high. Those with ischemic-type ST depres-
sion, with or without angina tend to have more extensive
coronary artery disease than those without, and the prognosis
is related to the severity of the disease (600,627).
We should add to this group patients identified by ambu-
latory electrocardiography (Holter). Those with silent ischemia
had an increased risk for adverse outcome (628–630).
It is clear that a significant number of patients will demon-
strate different degrees of coronary artery disease even though
they are totally asymptomatic. An important subgroup consists
of those who have a history of previous myocardial infarction.
Do we need to perform catheterization in every postinfarction
asymptomatic patient to detect mainly multivessel coronary
diseases?
Figure 10. Asymptomatic anterior (left) and posterior (right) myocar-
dial infarction: angiographic findings. LMT 5 left main trunk. Data
from Favaloro (399).
Table 17. Coronary Cine Angiography Associated With Cine
Studies of Other Vascular Territories in 500 Consecutive Patients
and Angiographic Findings in Coronary Arteries*
Cine Coronary Angiography Associated With Cine
Studies of Other Vascular Territories
No. (%)
of Pts
Selective arteriography of limbs 220 (44%)
Selective arteriography of neck vessels 160 (32%)
Abdominal aortography (with or without selective renal
arteriography)
90 (18%)
Selective arteriography of neck vessels and inferior limbs 30 (6%)
Angiographic findings in coronary vessels
1-VD 125 (25%)
2-VD 110 (22%)
3-VD 150 (30%)
LMCA disease 35 (7%)
Normal coronary arteries 80 (16%)
*Data from Favaloro (399). Abbreviations as in Tables 1, 3 and 5.
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There are two roads that may be followed. One is initial use
of noninvasive methods from a simple ergometric test to the
more complex cardiac radionuclide imaging and/or stress
echocardiography. Myocardial perfusion imaging shows that
the size and number of the perfusion defects are the best
indicators of the extent of severely obstructive coronary dis-
ease. Thallium 201 planar scintigraphy showed an average
sensitivity and specificity of 83% and 88% by visual analysis. A
recent study using technetium 99 perfusion has shown similar
results (631). Thallium 201 single-photon emission computed
tomography (SPECT) scintigraphy demonstrated an average
sensitivity and specificity of 89 and 76% respectively. SPECT
imaging yields better detection of individual coronary stenoses.
Positron emission tomography (PET), an expensive imaging
modality, showed higher specificity than SPECT both in the
diagnosis of patients and in identifying individual coronary
artery stenoses. Pharmacological myocardial perfusion imag-
ing (dipyridamole, adenosine and dobutamine) indicated high
sensitivity (90% average) and acceptable specificity (70%
average). The special report of the AHA/ACC Task Force
(631) concludes that
because of the low positive predictive value of non-invasive
testing in asymptomatic patients, radionuclide techniques are
not ordinarily recommended as a screening strategy for coro-
nary artery disease. However a stress radionuclide test is
valuable in asymptomatic patients with positive exercise elec-
trocardiography stress test results, in that it may assist in
determining the need for coronary angiography.
At present, as the cost-effectiveness of newer techniques
and technologies becomes increasingly scrutinized, exercise
echocardiography (with or without dobutamine or dipyrida-
mole) (632–649) has demonstrated an overall sensitivity for
the presence of severely obstructive coronary artery disease of
91%. For identification of multivessel disease the overall
sensitivity and specificity are 73% and 70% respectively (640).
In summary, noninvasive evaluation is helpful and should
always start with a simple exercise test, taking into account its
limitations (650).
The second road is to directly perform cine coronary
angiography that, with accurate reading, provides the best tool
for detection of coronary stenoses and enables prediction of
probable risk in individual patients.
The final decision in asymptomatic patients should be made
in each individual starting with a careful analysis of the clinical
record. The data accumulated by the different non-invasive
tests are based on the patient population. As an example I will
be more inclined to advise cine coronary angiography for a
50-year-old male with a strong family history, presence of mild
hypertension and lipid abnormality and 1-mm ST-segment
depression on treadmill electrocardiography than on a 70-year-
old patient with a history of myocardial infarction one year
before, who stopped smoking, controls his hypertension, fol-
lows a low fat diet (normal lipid values), does regular exercise
including some sports, and who has 1-mm depression on
treadmill testing.
The Asymptomatic Cardiac Ischemia Pilot (ACIP) study
(586,651,652) was designed for comparison of three treatment
strategies (angina guided, ischemia guided, and revasculariza-
tion) intended to suppress asymptomatic ischemia detected by
ambulatory electrocardiography or exercise treadmill tests. Of
192 patients assigned to undergo revascularization 94 had
PTCA attempted, 79 had CABG performed and 19 did not
have any revascularization procedure because either the pa-
tient or treating physician refused after randomization. At 12
weeks the percentage of patients with no ischemic episodes on
ambulatory electrocardiogram was 70% in the CABG patients
vs 46% in the PTCA group. They remained practically un-
changed at one year (71% vs 52%). At the qualifying visit,
exercise-treadmill-test-induced ischemia was present in 80%
and 49% on CABG and PTCA patients, respectively. It
diminished to 10% and 30% at 12 weeks, and at one year it was
15% and 24%. Multivessel disease was present in 86% of
patients undergoing CABG and in 62% of patients undergoing
PTCA. One patient in the CABG group had experienced a
myocardial infarction and in the PTCA group three had had
myocardial infarction; two of the patients of the PTCA group
had repeat PTCA and four had CABG surgery. The silent
ischemic episodes were also reduced in the medically treated
group, but CABG was the most effective in reducing ischemia.
Up to 1983, as can be seen in Table 18, we had operated on
328 asymptomatic patients with three hospital deaths. We
continued this policy after we established the Institute of
Cardiology and Cardiovascular Surgery (ICYCC) of our Foun-
dation. From June 1992 to December 1996, 185 patients were
operated on, with three in-hospital deaths.
Recently, FitzGibbon and collaborators reported a long
follow-up of 118 asymptomatic patients operated between 1971
and 1979 (68% had triple-vessel disease and 15% left main
disease). With one exception all of them were younger than 45
years. At 15 years they had similar survival to that of symp-
tomatic patients that were operated on by the same group.
They concluded that there was “no reason why the same basic
surgical principles of treatment, namely relief of coronary
stenosis, should not be applied equally to all groups of
patients” (653).
Table 18. Coronary Bypass Operation in 328 Patients Without
Angina Pectoris*
Pt Characteristic
No. of
Pts
No. of
Deaths
Asymptomatic pts after previous MI 143 1
Asymptomatic pts with vascular disease in other
territories
77 1
Noncharacteristic thoracic pain 54
Valvular disease 34 1
Positive stress test 14
Fatigue 3
Family history or risk factor 3
Total 328 3
*Data from Favaloro (399). Abbreviations as in Tables 2 and 3.
25BJACC Vol. 31, No. 4 Suppl B FAVALORO
March 15, 1998:1B–63B CRITICAL ANALYSIS OF CABG: A 30-YEAR JOURNEY
Acute Myocardial Infarction
During the early years of myocardial revascularization when
the Vineberg approach was utilized, I was intrigued by the
discordance between clinical and pathological findings in pa-
tients who died suddenly or within a few hours in the early
postoperative period as a consequence of a large myocardial
infarction. Electrocardiography had documented acute myo-
cardial infarction as the cause of death. At autopsy (I used to
perform them with my colleagues from the pathology depart-
ment) it was not possible to detect the area of the infarction
macroscopically and even with routine microscopy it was very
difficult to define an acutely infarcted zone. “Insufficient time
had elapsed for the infarction to be recognized” was the
response of L. K. McCormack, in charge of the cardiovascular
section of the pathology department. Electron microscopy
showed afterward that most of the myocardial cells were intact.
In 1968 Cox et al (654) demonstrated, by dehydrogenate
staining after experimental ligation and sectioning of the
anterior descending branch of the left coronary artery, that
only ischemic changes (swelling of mitochondria on A bands
and loss of extramitochondrial enzymatic activity with preser-
vation of the normal myocardial architecture) were seen within
six hours of coronary ligation.
Physiologic observations of the ischemic heart and its
relation to oxygen consumption, as analyzed by Braunwald et
al and Sonnenblick et al (655–659), convinced me that if we
could increase quickly the reduced blood supply to the “in-
farcted area,” the contractile state of the myocardium could be
changed and certainly CABG was the way to do it.
The early experience that started in April 1968 was sum-
marized in Chapter Ten of one of my books (660) and in my
last contribution in Cleveland (15) before returning to my
home country:
Cardiovascular surgeons are on the doorstep of a more
aggressive surgical approach among patients with acute coro-
nary insufficiency. Although the present clinical experience is
limited (eighteen operations were performed upon patients
with impending infarction and eleven upon patients with AMI),
certain conclusions can be made: (1) Emergency coronary
cineangiography can be performed with minimal risk; (2)
Patients with impending myocardial infarction can undergo
operation with a low mortality rate and minimal complications.
These patients are ideal candidates. The operation can prevent
myocardial infarction; (3) When operations are performed
within 6 hours of an AMI, most of the heart muscle can be
preserved; (4) In patients with AMI and cardiogenic shock,
assisted mechanical circulation is mandatory as the first step.
Several contributions appeared in this early period, indicat-
ing that the operations could be performed with low operative
mortality and good clinical results (661–671).
The Spokane group (DeWood, Berg et al) (588,671–675)
accumulated the largest experience: 440 transmural infarctions
(84% in prior clinical class I and II) were operated on, with a
5.2% hospital mortality. In 261 patients with nontransmural
infarction, the hospital mortality was 3.1%. However, transmu-
ral anterior infarction showed a 14% hospital mortality, and in
all patients with triple-vessel disease it was 9%. Forty-three
patients in prior class IV had a 28% hospital mortality. The
mortality decreased (3.8%) in 291 patients that were placed on
cardiopulmonary bypass within six hours.
At ten years (675) the total mortality was 8%, 12% and
17.4%, respectively, for patients with single-, double- and
triple-vessel disease in transmural myocardial infarction. At
eight years the total mortality was 4.2%, 6.3% and 8.4%,
respectively, for single-, double- and triple-vessel disease in
nontransmural myocardial infarction. Patients who were oper-
ated on within six hours of the acute episode had a total
mortality of 8.2% vs 21% among patients with late reperfusion.
The authors analyzed the early mortality with conventional
medical therapy at their community (11.5%) and the mortality
among survivors reported in the literature in those years (8%
to 15% during the first year, 5% to 10% per year thereafter)
(581,676,677). Even though they recognized their patients
probably included many less likely to benefit from surgical
reperfusion, they stated that only controlled randomized trials
could be definitive. The Spokane experience was criticized as
an unproved experimental clinical trial (678,679) mainly be-
cause the presentation of the data was incomplete, lacking the
usual parameters utilized in clinical trials. DeWood et al
answered this criticism (680) by presenting a complete report
of 387 patients (200 on conventional therapy and 187 who
underwent emergency CABG) with a hospital mortality of
11.5% vs. 5.8% on the medical and surgical groups respec-
tively. Early reperfusion (,6 hours) resulted in a lower mor-
tality rate (2% vs. 15.5%). Follow-up at 10 years demonstrated
a mortality of 41% in the medical group vs. 27% in the surgical
group. I believe they showed that early reperfusion can be
accomplished in a large number of patients with low operative
mortality (except in patients with three vessel disease and
anterior infarction) and excellent survival in long-term follow-
up. It should be emphasized that these results were accom-
plished in a decade of mediocre myocardial protection.
We continued our efforts in Buenos Aires. Experimental
work in monkeys (681) confirmed that within six hours most of
the myocardial cells could be reconstituted if blood supply was
reestablished. Up to 1983, 583 patients were studied with cine
coronary angiography in the acute and subacute phase of
myocardial infarction without mortality, confirming once more
that visualization of the coronary tree can be done as an
emergency procedure, following the original contribution of
Begg et al (682). Sixty-six percent of 148 uncomplicated
myocardial infarctions had cine angiography within the first ten
days. Most of the studies were performed among 340 patients
who developed angina (50% were studied within the first 10
days); 95 patients underwent cine angiography due to acute
mitral insufficiency, ventricular septal defect, intractable ar-
rhythmia or severe heart failure. Analysis of the cine coronary
angiography of patients with post-AMI angina (683) can be
summarized as follows: type I, single severe obstruction of a
coronary artery that produces a myocardial infarction smaller
than the irrigated area; type II, obstruction similar to type I
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and additional lesions in other coronary vessels; type III, total
occlusion of a coronary artery that produces a small infarction
because of partially adequate noncompromised collateral cir-
culation; type IV, total occlusion of a coronary artery that
produces a small infarction because of the presence of partially
adequate compromised collateral circulation; type V, total or
subtotal obstruction that produces a large myocardial infarc-
tion with concomitant obstruction in other coronary artery
territories; and type VI, total occlusion of a coronary artery
that produces an acute ventricular aneurysm with concomitant
obstruction in arteries supplying other vascular territories.
Collateral circulation is compromised when the artery that
supplies it presents a critical obstruction. Careful analysis of
the cine angiography allowed us to perform CABG in 174
patients (44.7% operated on within 10 days) with seven deaths
(4.1%).
Several contributions had appeared in the literature since
the mid-1970s (673,684–709). Analysis demonstrated that (a)
the operations could be performed with a low mortality except
on emergency indications within the first 24 hours. The risk
was higher when CABG was done during the first week
(;8%); (b) mortality increased with clinical status: age, Q
wave myocardial infarction, anterior infarction, triple-vessel
disease and low ejection fraction; (c) operation limited infarc-
tion size and enhanced muscular recovery with improvement of
left ventricular function; (d) long-term follow-up showed sur-
vival rates similar to those of the population with a history of
a previous remote infarction that underwent CABG; (e)
operation could be life-saving in patients with cardiogenic
shock even though the mortality varied between 12% and 30%.
Only one series reported a mortality of 54.5% (six deaths in
eleven patients) (702). Utilization of intra-aortic balloon coun-
terpulsation improved the hemodynamic status, decreasing
operative mortality. Even with present medical treatment
(population from 1992 to 1993) an international registry found
a 71% mortality in patients with shock (710).
Post-AMI angina constitutes an expanding subset of pa-
tients from the 1980s. Our results, already mentioned, were
confirmed by Jones (711) and Levine (712). Later, several
contributions (696,703,713–722) demonstrated the feasibility
of CABG in this challenging group of patients, with a hospital
mortality from 0% to 10.5%. Of course the series were not
entirely comparable. Significant differences in age, degree of
clinical instability, extent of disease and status of the left
ventricle can indeed be found. Medium and long-term follow-
ups were gratifying; actuarial curves demonstrated a survival of
95.3% at 18 months, and 85% at five years.
These results contrast dramatically with the reports from
medical treatment. Chaturvedi et al (723) showed a mortality
of 23% within three months after discharge and 37% within
one year, and Schuster and Bulckley reported an overall
mortality of 56% at a mean follow-up of six months (590). As
we know, angina suggests the presence of viable ischemic heart
muscle. In this group the incidence of a second infarction in
medically treated patients within one year varies from 13% to
86% (715,724–729) with an early mortality of 29% if the
second infarction is transmural (712).
In conclusion early experience demonstrated that patients
with APAMI should be carefully monitored. Cine coronary
angiography is indicated in the majority of them and CABG
can be performed with low mortality.
The introduction of fibrinolytic agents has opened a new
era in AMI. At the beginning, intracoronary streptokinase
(SK) was utilized. The results of some early clinical (730–735)
and randomized trials (736–739) reported a lower mortality
and improved left ventricular function after coronary reper-
fusion. A small number of patients was included. In 1983,
250 patients were enrolled in a multicenter randomized
community-based study (740,741). Reperfusion was achieved
in 68% of the treated group, with an overall 30-day mortality of
7.2% vs 11.2% in the control group. At one year the reduction
persisted only among patients in whom perfusion was re-
established. This early experience demonstrated that a high-
grade stenosis remained in a significant number of patients. As
a consequence, a complementary combined approach with
early PTCA and CABG was reported (693,742–747).
It has been demonstrated through large-scale randomized
trials in patients with AMI starting in 1979 (738,748–764) that
when intravenous thrombolytic therapy is administered within
twelve hours after onset of symptoms it reduces hospital
mortality and the survival advantage persists. The late mortal-
ity was also low (765,766) particularly when comparing it with
previous series antedating the use of thrombolytic therapy
(767).
Nevertheless, Van de Werf (768), in a recent meta-analysis
of long-term benefits of intravenous thrombolytic therapy
based on more than 40,000 patients from well-controlled trials,
showed that the risk of death after one month was the same in
survivors of an AMI whether or not thrombolysis was given on
admission. In 18,826 patients who were treated within twelve
hours, 3.9% died during the following five months vs 4%
(18,014 patients) of the placebo group. In patients treated
within three hours the mortality rates were 3.7% vs 3.6%,
respectively. After six months the death rate was also very
similar with or without thrombolytic therapy. Van de Werf
posed a very important question: “Why is not there any extra
benefit after hospital discharge?”
Perhaps a critical analysis of the data accumulated could
help us. In several trials without thrombolytic agents retrospec-
tive analysis showed that patency of the infarct-related artery
appears to be important (769–771). Dalen et al (759) in the
TIMI trial of 1988 demonstrated that within one year the
mortality in 289 patients was 15% if the arteries were occluded
at 90 minutes vs. 8% if the arteries were patent.
It has become clear that even with the best thrombolytic
regime available, the percentage of early true reperfusion
(TIMI flow 3) is disappointingly low (;50%) (772–776). Even
though earlier reports had suggested that left ventricular
function, infarction size, and morbidity may be inferior in
patients with TIMI 2 flow rather than TIMI 3 flow after
thrombolysis (773,774,777), recently several reports clearly
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confirmed (778–782) that patients with TIMI 2 flow should be
considered an inadequate result of therapy. Recurrent isch-
emia is significantly higher in patients with TIMI 2 flow (22.9%
vs 16.9%). Reocclusion was observed more frequently (10.4%
vs 2.2% between 18 and 36 hours) and hospital mortality was
also higher (6.7% vs 3.8% in a pooled data of 3,960 patients).
Global and regional left ventricular function are better pre-
served in patients with complete TIMI 3 infarcted vessel
patency than in those with TIMI 2 flow. Patients with TIMI 2
flow had a lower residual luminal diameter in the culprit lesion
than patients with TIMI grade 3 flow. The TIMI investigators
(783) had shown that the one year mortality rate in patients
with ,60% diameter stenosis in the infarcted related artery
was 1.6%, compared with 4.4% in patients with .60% stenosis.
The European Cooperative Study Group (780) showed that at
five years, patients with TIMI 2 flow had mortality rates similar
to those with TIMI 0 and 1 flow. Consequently we can
conclude that only TIMI 3 flow should be regarded as patency
in the sense of predicting a good clinical outcome.
Recurrent ischemic events are known to increase after
thrombolytic therapy (749,754,784,785). They are present
within one week in from 19.2% (786) to 22.9% (781). They
increase to 25.8% at two weeks (787) and 29% within six weeks
(788–791). Therefore, it is not surprising that reocclusion
occurs in 5% to 10% before discharge (774,792–794), and
12.2% (11.8% to 16.3%) with standard tissue-type plasmino-
gen activator (t-PA) (795–803), 7.2% (5.2% to 9.1%) with
accelerated t-PA (798,804–807), 4% (3.1% to 6.9%) with
streptokinase (SK) (774,808–813) and 3.8% (1.6% to 5.1%)
with anisoylated plasminogen SK activator complex (APSAC)
(805,810–815) within six weeks, with a concomitant high
incidence of reinfarction (751,761,762,816), particularly in
patients with non-Q wave infarction (817,818).
In the GUSTO trial the incidence of reinfarction within
four days was 3.4% in the subcutaneous SK group and 4% in
the other 31,180 patients. The hospital mortality was signifi-
cantly elevated (between 16.8 and 20% in this reinfarction
group) in comparison with the overall mortality (between 6.3%
and 7.4%) (819). The incidence of reinfarction increased to
6.5% within six weeks (788–790). The TIMI II investigators
had shown that at three years nonfatal reinfarction is an
independent predictor of death, more powerful than other
important patient characteristics (820).
It is possible that more potent inhibitors of platelet action
such as platelet fibrinogen receptor will increase the degree of
lysis and lessen rethrombosis (821). The tools of molecular
biology and genetic engineering modify plasminogen activator
function and contribute to a new “third generation” of throm-
bolytic agents (reteplase, staphylokinase, t-PA-scu-PA chi-
mera, bat-t-PA, TNK mutant, antibody-targeted plasminogen
activators and antibody targeting of adjunctive agents) that
have been recently analyzed by Bode et al (822). They believe
these show promise to improve clinical outcome and perhaps a
reduction of intracranial bleeding (between 0.5% and 1.5% in
patients with the present treatment). However, megatrials will
be required because the absolute reduction in mortality with
our current thrombolytic therapy ranges between 2% and 4%.
Hirudin and hirulog, highly specific antithrombin agents,
seem to be more effective than heparin in the prevention of
reocclusion after t-PA (823,824) or SK (825). However, current
patient numbers are small and hirudin is associated with more
cerebral bleedings than heparin (824,826–828).
I think it is important to remember that patients receiving
thrombolytic therapy constitute a minority extracted from
consecutive patients with myocardial infarction seen in the
emergency room (ER).
Cragg and collaborators analyzed 1,471 patients admitted
with an AMI from April 1986 to June 1988 (829). Only 230
(16%) received thrombolytic therapy. The comparison with the
other 1,144 demonstrated that they comprised a low-risk
population. Mortality was fivefold higher among ineligible
patients. These findings were consistent with data from GISSI
I (749) and ISIS-2 (754) of 1986 and 1988 respectively. The
National Registry of Myocardial Infarction (NRMI) showed
that among 240,989 patients (September 1990 to December
1993), 35.1% received thrombolytic therapy (830). In 269,035
patients registered between July 1994 and December 1995,
only 30.3% (81,577 patients) received thrombolytic therapy
(personal communication, W. J. Rogers).
Most of the patients reported in the literature with myo-
cardial infarction and treated with thrombolytic agents are
,65 years of age, and although only 13% of the U.S. popula-
tion is .65 years of age, 80% of all hospital deaths due to
myocardial infarction are in this age group (831).
Even though the analysis of the cineangiography is insuffi-
cient, in some of the trials the proportion of patients with
tr iple-vessel disease is quite low (7% to 20%)
(740,766,767,780–783,796,818,832–846), if we compare these
data with the populations reported in the prethrombolytic era
(23% to 50%) (848,849).
What about non-Q wave myocardial infarction? Non-Q
wave myocardial infarction is often associated with continued
perfusion deficit to the infarcted zone because of subocclusive
flow-limiting stenosis (849–851). Total coronary occlusion
occurs in only 32% of these patients (849). In several trials the
mortality rate in patients with ST segment depression was not
influenced by thrombolytic therapy (749,764,830,852). It is well
known that patients with non-Q wave infarction have a rela-
tively low in-hospital mortality rate (853,854). However, recur-
rent ischemia, reinfarction and death frequently occur after
discharge (855–858).
Langer et al., in the LATE study (859), randomized 644
patients with non-Q wave myocardial infarction to treatment
with t-PA and 665, to placebo. The benefit conferred by the
administration of t-PA was evident at 35 days (death: 5.4% vs.
9.6%; reinfarction: 1.9% vs. 5.8%). After one year, mortality
was 10.6% vs. 16.2% and reinfarction 6.4% vs. 10.8%.
Braunwald and Cannon (860) found the results interesting,
surprising and provocative, mainly because thrombolytic ther-
apy provides a substantial benefit in the subgroup of patients
with ST-segment depression where current treatment leaves a
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lot to be desired. Langer suggested that additional prospective
rigorous trials should be carried out to corroborate their
results. I do believe cine coronary angiography is indicated in
the early stages.
CABG in the Thrombolytic Era
CABG also plays a role in the thrombolytic era. Several
publications appeared in the early and mid 1980s (742,861–
873) and, even though they report small numbers of patients,
on review it is evident that they comprise patients at high risk,
on whom CABG was done frequently on an emergency basis,
during the first 24 hours. After these preliminary attempts in
1988 Petrovich (874) published the results of 388 patients
operated after being treated with intracoronary or intravenous
streptokinase (SK) and compared them with 318 patients
treated medically after receiving the same thrombolytic drug.
The average interval from SK to CABG was 4 6 3.2 days. In
the surgical group 70.3% had shown multivessel diseases with
severe residual stenosis on the culprit vessel. The in-hospital
mortality was 3.6% vs 9.4% in the medical group. No data were
available after discharge.
In 1991 Kereiakes et al reported the overall results from the
TAMI study group (875,876), partially documented in two
previous publications (877,878). Three hundred and three
patients were operated on after being treated with t-PA,
urokinase or both and compared them with 1,387 patients who
received the same thrombolytic agents. As a group, patients
having surgery were older and more often had diabetes or a
prior myocardial infarction; 20% had single-vessel disease and
46%, triple-vessel disease. In the medical group, 56% had
shown single-vessel disease and only 11%, triple-vessel disease.
The operation was done as an emergency procedure within the
first 24 hours in 36 patients (24% in cardiogenic shock).
Mortality was 17% in the emergency group and 5% in the
deferred group (overall hospital death was 6.6%). The medical
group showed a 5.9% mortality. At three years death was
similar: 7.2% in the CABG group and 6.2% on the medical
group, non-fatal myocardial infarction occurred in 5.3% and
8.4% in the surgical and medical groups respectively. The
degree of recovery of global and regional (infarct zone) left
ventricular function in the surgical population clearly exceeded
the degree of functional recovery noted following thrombolysis
alone.
The results were quite similar during hospitalization but
certainly they were comparing two different populations. I
think it is more appropriate to state that as a consequence of
CABG, a group of patients at high risk had early results similar
to those at low risk (triple-vessel disease: 46% vs 11% in the
medical and surgical groups, respectively). The same com-
ments can be made with the outcome at three years. In
addition 18% of the medical group required PTCA or CABG
vs. 7% in the surgical group.
In 1994 Nicolau presented another important series (879):
128 patients were operated on and compared with 147 patients
receiving medical treatment. All patients had received SK.
Cine angiography was performed between 48 and 72 hours.
Multivessel disease was present in 76.8% and 40.7% of the
surgical and medical groups, respectively. Hospital mortality
was 4.7% in the surgical group vs 10.9% in the medical group.
All the patients who left the hospital were followed for six
years. Survival was 68.4% and 86.4% in the medical and
surgical groups, respectively.
In 1995 CABG after thrombolysis was analyzed in the TIMI
II Phase II trial (845). The 390 patients who underwent bypass
were classified into two groups: (A) 54 patients who underwent
surgery within 24 hours after entry into the trial or within 24
hours of PTCA performed within 42 days of enrollment; (B)
336 patients who underwent CABG between 24 hours and 42
days after entry. Multivessel disease was present in 51% and
65.1% in groups A and B, respectively (triple-vessel disease in
11.8% and 25.2%). Only one operation was categorized as
elective in group A, and 66.7%, in group B. Sixty-two percent
had internal mammary artery conduits (only 18.5% in group
A). Perioperative mortality was 5.6% (16.7% and 3.9%, re-
spectively, in group A and B). Perioperative myocardial infarc-
tion was 6.2% (5.6% and 6.2% in groups A and B). Among 322
survivors there were only seven deaths during the first year
(mortality rates were 2.2% and 1.9% in groups A and B). Only
one patient had a documented myocardial infarction, during
the second year. No patients in group A died and only six
patients in group B died.
In summary: (a) intravenous thrombolytic therapy for
evolving myocardial infarction is associated with a significant
increase in subsequent coronary revascularization compared
with patients receiving conventional therapy (759,838,880); (b)
CABG is performed in patients at high risk with an acceptable
operative mortality except on emergency indications within the
first 24 hours. In this particular group, the majority is in poor
hemodynamic condition, including patients in cardiogenic
shock and in the TIMI population, 58% required intra-aortic
balloon; (c) blood loss increased in CABG done in patients
receiving thrombolytic agents, particularly when surgery is
performed during the first 24 hours, when hemorrhagic events
and reoperations are common. The cooperation of an expert in
coagulation therapy is mandatory in the operating room and in
the immediate postoperative recuperation.
PTCA in the Thrombolytic Era
The first PTCA for AMI was performed in 1981 at the Mid
America Heart Institute (881). Thereafter they accumulated a
significant experience demonstrating that angioplasty can be
done as an emergency procedure with a high success rate and
low morbidity and mortality (882). Costantini et al, based on
previous experimental work performed at the Cedars-Sinai
Medical Research Institute since 1975 (883), started PTCA in
AMI in Argentina in 1982. Since 1985 several publications
appeared, ten of them being compiled by Eckman et al (884) in
a meta-analysis. From 2,073 patients, the success rate was 91%
with a hospital mortality of 8.3%.
The utilization of PTCA after thrombolysis, although it is a
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widely used technique, remained a controversial issue. Up to
1992 some trials suggested a certain benefit (835,885–888) but
other trials showed no advantage (757,787,796,801,832,889–
898). In 1993 three prospective randomized trials (789,790,
899) appeared simultaneously in the New England Journal of
Medicine showing a better clinical outcome for primary angio-
plasty compared with standard thrombolytic therapy, particu-
larly in the PAMI trial (789): the incidence of deaths and
reinfarction was 5.1% for PTCA vs 12% for thrombolysis. The
reduction was particularly marked in patients .65 years of age
(8.6% vs 20%). Recurrent ischemic events were markedly
reduced in the patients treated with PTCA compared with
t-PA-treated (10.3% vs 28%). The independent beneficial
effect of angioplasty on freedom from death or reinfarction
was maintained at six-month follow-up (death occurred in
8.2% vs 17%). Certainly these publications resulted in an
increased utilization of PTCA in AMI.
Recently a critical analysis was reported by Michels and
Yusuf (900). They carried out an excellent quantitative over-
view of the randomized clinical trials, dividing them into
different groups. The seven trials that compare primary PTCA
vs. thrombolytic therapy demonstrated a considerable reduc-
tion in mortality with PTCA at 6 weeks (3.7% vs 6.4%, OR
0.56, 95% confidence interval, 0.33 to 0.94). When death and
nonfatal myocardial infarction were combined, the reduction
was similar (6.1% vs 11%). This benefit has been confirmed to
a lesser degree by the GUSTO IIb Trial: within 30 days death,
myocardial infarction, and stroke comprised 13.1% of the
patients in the thrombolytic group vs 9.6% of the PTCA group.
These clinical benefits greatly exceed those observed in the
GUSTO I Trial, in which t-PA was found to be a superior
regime, as has been pointed out by Grines (901). In the t-PA
group 30% of the patients also had PTCA during hospital
admission (in 25% of the cases the cine angiographies were
done as emergencies). If we add the GUSTO IIb Trial to the
seven previous studies, we find that death in the PTCA group
was 4.7% vs 6.7% in the thrombolysis group, and death plus
myocardial infarction was 7.8% vs 11.6% in the PTCA and
thrombolysis groups, respectively. Once again the t-PA group
is not a pure thrombolytic population. This is a common
finding in most of the trials, mainly as a consequence of
recurrent angina. In the TIMI Trial Phase II (787), among the
entire group assigned to the conservative strategies, 262 pa-
tients (16.1%) had PTCA and 170 patients (10.5%) had
CABG. In the PAMI Trial (789) the t-PA group required
PTCA in 24.5% of the cases.
The results of the Primary Angioplasty Registry (902,903)
can be also utilized for comparison because patients with usual
contraindications to thrombolytic therapy were excluded to
provide a population similar to previous U.S.-based thrombo-
lytic trials. In 258 patients death, reinfarction and stroke
occurred in 8% of the population.
In conclusion, the analysis of the various trials suggests: (a)
primary PTCA may be more beneficial than thrombolytic
therapy in AMI; (b) besides the reduction in hospital mortality,
angioplasty results in a smaller infarct size and a better
preserved left ventricular function, probably due to early and
improved coronary flow (904,905); (c) PTCA also reduced the
incidence of recurrent angina, reinfarction and reocclusion
within six months (786,789,790,903–910) commonly found in
thrombolytic trials. Nevertheless these remain significant: re-
current ischemia 10% to 15%, reinfarction 3% to 6% and
reocclusion of the infarcted-related artery 5% to 10%, in
hospital and six months results, respectively (901).
PTCA was also used as an adjunct to thrombolytic therapy.
Michels and Yusuf (900) also analyzed several trials categoriz-
ing them according to four different approaches: immediate
PTCA compared with no PTCA, early PTCA compared with
no PTCA, delayed PTCA compared with no PTCA and
immediate PTCA compared with delayed PTCA. Mortality at
six weeks showed trends toward increased risk in the more
aggressively-treated group (immediate and early). Neverthe-
less, in none of these categories were there significant differ-
ences.
Only a few trials included patients in whom PTCA was
performed on occluded vessels. As an example, in the Phase II
TIMI Trial, 177 patients (12.1%) were excluded from the
group of invasive strategies because they showed total occlu-
sion. As a consequence the experience with rescue PTCA is
limited (812,844,911–914). Its indication remained controver-
sial because of an imperfect success rate, the high mortality of
patients with failed angioplasty which outweighed the clinical
benefit, the high incidence of reocclusion and the increased
incidence of bleeding complication at the access site. There-
fore rescue angioplasty should be a subject of future clinical
trials in AMI. I believe patients with TIMI 2 flow should be
included. Nevertheless PTCA appeared to be useful in the
prevention of death or severe heart failure with improvement
in exercise ejection fraction in patients with anterior AMI
(844).
The benefit of PTCA in anterior infarction has been
recently confirmed by the PAMI investigators (915). Com-
pared with t-PA, in-hospital mortality was reduced by angio-
plasty (1.4% vs 11.9%). PTCA also reduced death and rein-
farction (1.4% vs 18%), recurrent ischemia (11.3% vs 28.4%)
and stroke (0% vs 6%).
The overall analysis of the data on primary PTCA is
promising and encourages its utilization, but it is important to
remember that the trials analyzed were conducted in a few
highly qualified centers and perhaps the outcome would be less
impressive if the procedure were performed in hospitals with
low volume operators (916,917). In the MITI Trial (AMI)
(918) PTCA was performed in 801 patients in high-volume
hospitals with a mortality of 4.5%. In 207 patients the proce-
dure was done in low-volume hospitals with a mortality of
8.1%.
Even though we do not have enough data regarding long-
term follow-up of patients submitted to PTCA in AMI, due to
the high incidence of early restenosis that varies between 19%
(919) and 51% (920) (recently Horrigan and collaborators
[921] in a meta-analysis of 860 patients found an average of
43%), it is logical that acute angioplasty of the culprit lesion is
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a temporary partial solution mainly among patients with
multivessel disease.
Of particular interest is the application of PTCA in patients
with cardiogenic shock due to AMI. As we know cardiogenic
shock is the leading cause of death in patients hospitalized with
AMI. The incidence (;8%) and mortality (;80%) remained
unchanged (922) under the traditional medical treatment.
Recently, Stone (923) reviewed 18 publications in which PTCA
was applied in 626 patients with an overall mortality of 46% (it
varied between 18% and 58%). Results of an international
registry (710) showed a 60% mortality in the PTCA group.
Patients clinically selected to undergo cardiac catheterization
were significantly younger and had a lower mortality than those
not selected (51% vs 85%) (710). Certainly I believe PTCA
should be considered the first choice for this high-risk group of
patients.
Reports of comparison of the relative benefits of primary
coronary angioplasty and thrombolytic therapy are open to
some criticism. Many times the data were not properly pre-
sented. As an example Every et al (918) from the MITI project
analyzed the results of 1,050 patients treated with primary
angioplasty and compared them with 2,095 in the thrombolytic
group. There was no difference in mortality during hospital-
ization (5.6% vs 5.5% in the thrombolytic and PTCA groups).
At three years, patients treated with thrombolytic therapy were
less likely to have undergone coronary angiography (19.7% vs.
28.3%), coronary angioplasty (15.9% vs. 18.8%) and similar
proportions had CABG, but there was no difference in long-
term survival. The high-risk group had similar results during
hospitalization (mortality 8.1% vs. 8.7% for thrombolysis and
PTCA, respectively). A slightly better survival was noted at
three years in the thrombolytic group (17.8% vs. 24.8%).
However, they did not emphasize that 74% of the thrombolytic
group underwent angiography and 32% underwent PTCA
during hospitalization. Consequently this would be a clinical
trial that compares primary PTCA vs. thrombolytic therapy
plus primary PTCA.
It is interesting that in the same journal Lange and Hillis
(924) in a “clinical debate” related to the Every article argue
that thrombolytic therapy should be the initial therapy and
Grines (925) favors coronary angioplasty. The former believes
that the preferred treatment should be thrombolysis because it
can be applied more quickly, safely and expertly, but he did not
mention a word on patency, recurrent angina, reocclusion and
reinfarction. Of course Grines is in the “opposite corner”
emphasizing all this setback from thrombolysis, but without a
word on the high rate of restenosis registered in the literature.
On the contrary, “reocclusion after angioplasty may be related
to factors that can be easily corrected.” How difficult it is to
avoid personal bias!
A summary of all the publications related to primary PTCA
vs. thrombolysis in AMI has been a tremendous effort by Lieu
et al (926) aimed at providing a scientific groundwork to assist
physicians in deciding which intervention is indicated. It is
important to remember that the numbers and percentages are
averages of a certain number of patients. The clinical stratifi-
cation and the catheterization data, of course, are not in-
cluded. The tables will serve only as a guide for a broad
orientation.
Stenting in AMI
Initial series of stent placement reported a disappointingly
high recurrence of stent closure (;25%) (927,928). The inci-
dence increased with emergency stent placement (929). It was
held that one of the most important factors associated with
stent thrombosis is the presence of intracoronary thrombus
before or after implantation and, as we know, the acute
coronary syndrome is commonly associated with intracoronary
thrombus. It was also emphasized that no antithrombotic
regimen was identified as being effective in prevention of
thrombosis in a suboptimally deployed stent (930). As a
consequence it was illogical to think that stent would have a
therapeutic role in patients with AMI.
Nevertheless the contributions of Goldberg (931) and Co-
lombo (541) and co-workers demonstrated that, by means of
intravascular ultrasound and with conventional implantation
techniques, stent deployment was suboptimal in up to 87% of
the cases with incorrect apposition of the device to the
coronary surface. They therefore suggested additional high
pressure noncompliant balloon angioplasty to fully expand the
stent.
Several investigators using ultrasound progressively dimin-
ished and finally stopped anticoagulation regimen and ob-
served very low closure rates with combined aspirin-ticlopidine
treatment, as a consequence of Morice et al contributions
(932–934).
Mak and collaborators (935) reported preliminary data of a
multicenter trial evaluating the ultrasound criteria proposed by
Colombo and colleagues. From 2,630 patients with at least
3,141 stents using antiplatelet agents without warfarin, only 33
(1.3%) have developed stent thrombosis (two thirds of these
patients did not have ultrasound imaging). At present, full
antiplatelet therapy without ultrasound guidance but with
“blind” high pressure angioplasty of .12 atmospheres, has
become routine clinical practice. Recently several reports
(927,928,936–943), although with small numbers of patients,
have shown that stents can be applied in patients with AMI
with a high success rate and significantly low rates of restenosis
and reocclusion.
The multicenter PAMI Stent Pilot Study is now investigat-
ing the role of stenting as a reperfusion strategy in patients
with AMI (901). Preliminary data in 125 patients showed that
stents were successfully deployed in 99% with no death or
reinfarction and a low rate of recurrent ischemia (2.4%).
Repeat revascularization (PTCA or CABG) was needed in
0.8% of the patients. Aspirin and ticlopidine were given.
It seems that primary stenting may be safely performed in
patients with AMI with good clinical results. Further experi-
ence and long-term follow-up results are needed. The intro-
duction of more potent antiplatelet agents, such as the TE3
glycoprotein IIb/IIIa receptor antagonist may further reduce
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the incidence of complications and recurrent ischemia. Never-
theless stents cannot be applied in all the patients mainly
because the arterial diameter should be .2.5 mm. In the
PAMI Stent Pilot Study, 31% of the patients were considered
ineligible for stent placement “if they had small vessels (diam-
eter ,2.75 mm), if .2 stents were required, if there was a huge
residual thrombus, if there was a possiblity that a stent would
be needed in the ostium of the left anterior descending
coronary artery or left circumflex, if major side branches were
in jeopardy, or if delivery or expansion of the stent might not
be feasible.” Coincidentally, for similar reasons, stent was not
attempted in 32% of the patients reported by Saito (944).
Comments on Thrombolysis, PTCA and
CABG in AMI
At present thrombolysis, PTCA and CABG may be per-
formed in patients with AMI. As in many other issues in
medicine opinions are divided. We should try to make deci-
sions and draw up guidelines on such an important subject,
bearing in mind that each year 900,000 people experience AMI
and roughly 225,000 die for the same cause in the U.S. The
following comments are the result of a critical analysis of the
guidelines for the management of patients with acute myocar-
dial infarction of the ACC/AHA Task Force Report (945).
A clinical examination that only takes a few minutes, gives
us important information. We know that infarct-related mor-
tality increases with age, female gender, a history of chronic
angina, previous infarction, hypertension, diabetes and the
presence of peripheral vascular disease (946–950). Significant
tachycardia (.100 per minute), hypotension, signs of conges-
tive heart failure, atrial and ventricular arrhythmias, persisting
angina and persisting ST segment depression indicate that
patients in this category are at high risk.
The classification by Killip and Kimball (951) is very useful
thanks to its simplicity and easy application. The four groups
are related to the extent of the left ventricular dysfunction. The
TIMI, Phase II co-investigators (952) analyzed the presence of
eight risk factors before thrombolytic therapy was adminis-
tered: age $70 years, female gender, a history of diabetes
mellitus or previous myocardial infarction, electrocardio-
graphic evidence of evolving anterior infarction or atrial
fibrillation, evidence on physical examination of mild pulmo-
nary congestion, hypotension (systolic pressure ,100 mm Hg),
and sinus tachycardia (heart rate .100 beats/min).
Among 3,261 patients, 864 had no risk factors and the
mortality rate at six weeks was only 1.5%; for those who had
one risk factor mortality was 2.3% (1,384 patients); for two risk
factors, 7% (689 patients), for three, 13% (231 patients) and
.4, 17.2% (93 patients).
Therefore clinical examination and the presence of risk
factors, easy to remember and without a numeric score, as in
the Peel (953) or Norris (954) indices, can clearly categorize
patients at low and high risk.
A 12-lead electrocardiogram (ECG), for primary screening,
will identify three groups: (a) ST segment elevation or new left
bundle branch block (LBBB). Most of these patients will
evolve into Q-wave myocardial infarction; (b) isoelectric ST
segments but sharp symmetrical T-inversion. A small subset
will evolve into a Q-wave myocardial infarction; (c) ST seg-
ment horizontal depression usually striking in multiple leads,
especially precordial leads. It generally indicates severe suben-
docardial infarction.
Even though between 1976 and 1987 several publications
(955–966) analyzed the utilization of echocardiography in
AMI, the contributions by Sabia et al (967,968) demonstrated
that regional wall motion abnormalities (RWMA) (carried out
with two-dimensional echocardiography in 180 patients in the
ER) that occur within seconds of coronary occlusion (969,970)
increase the diagnostic yield for AMI compared with conven-
tional approach, using clinical and ECG information. Even
though RWMA cannot differentiate between ischemia and
necrosis, it can detect the extent of myocardium involved and
it is a useful predictor of in-hospital complications. In addition
RWMA provides information concerning the status of the
myocardium remote from the region of acute injury and this
may suggest severe stenosis in coronary arteries that supply
these beds and therefore be indicative of multiple coronary
artery disease.
As we know left ventricular systolic function is a potent
independent predictor of survival (591,600,767,946,971–975).
Analysis of left ventricular systolic dysfunction (LVSD) by
echocardiography in 171 patients (968), also performed in the
ER, can help us predict events occurring within 48 hours of
admission (cardiac-related death, nonfatal myocardial infarc-
tion, serious arrhythmia and coronary revascularization).
When LVSD was present, events occurred in 26.9% of the
patients vs. 3.3% when LVSD was absent.
The introduction of myocardial contrast echocardiography
(976,977) with the possibility of new contrast agents adminis-
tered intravenously (978) constitutes a new technique that will
take its place among investigations during the acute phase of
myocardial infarction.
The laboratory plays an essential role in establishing the
final diagnosis of myocardial infarction. Creatinine kinase MB
is the current standard. Rapid whole blood bedside assays of
cardiac specific troponin T (cTnT) and I (cTnI) are now
available; increase in serum levels occurs early (979–981). The
analysis of the ECG and the serum cardiac enzymes will finally
categorize AMI into Q waves and non-Q waves.
Balloon flotation right heart catheter monitoring is very
helpful in patients with early signs of left ventricular deterio-
ration. Pulmonary capillary wedge pressure and cardiac output
will help in evaluation. Of course, its utilization is mandatory in
patients with cardiogenic shock.
Patients at high risk should be sent directly to the cardiac
laboratory for emergency cine angiography and concomitant
PTCA in most. After careful review, patients with severe left
main coronary artery disease, left main equivalent, or three or
more proximal obstructions will be sent for CABG, with or
without previous PTCA of the culprit lesion. It is important to
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remember that survival after AMI is determined by the infarct
size and the capacity of remote, non-ischemic myocardium to
support the systemic circulation by hypercontractility (982). A
recent report by Jaarsma et al (983) showed a 69% mortality in
patients who did not have remote hypercontractility. A previ-
ous contribution by Schuster and Bulckley (590) reported a
72% late mortality rate in patients with “ischemia at a dis-
tance.” Certainly, remote myocardium may become relatively
ischemic if it is supplied by severely stenotic coronary arteries
and is called upon to increase contractile function. Patients in
cardiogenic shock should be sent immediately to the cardiac
laboratory for possible PTCA as the only chance to reduce the
extremely high mortality with the present medical treatment
(926).
Patients in the low-risk category with ST segment elevation
or LBBB who have no contraindications should be treated with
intravenous thrombolytic therapy, watching their evolution
closely. The preliminary stratification can change within a few
hours.
Since DeWood’s fundamental contribution we know that
occlusive coronary thrombosis is present in more than 90% of
patients with ST segment elevation (588). Thrombolytic ther-
apy should be initiated as soon as possible, including patients
with LBBB that may obscure the electrocardiographic diagno-
sis. The incidence of acute thrombosis is low in patients with
modest ST segment depression (849,850,984) and thrombolytic
therapy has proved ineffective and even harmful (764).
Early discharge after thrombolytic therapy can be accom-
plished in low-risk patients with uncomplicated myocardial
infarction (absence of reinfarction, ischemia, stroke, heart
failure, balloon pumping, emergency cardiac catheterization
and, of course, early CABG within four days), as has been
demonstrated in the GUSTO Trial (846).
What should be done before discharge in the large group of
low-risk patients? Following a conservative approach in pa-
tients with definite signs of reperfusion a submaximal exercise
test (5 mets) is indicated in patients who can exercise.
Symptom-limited exercise has been suggested (985,986). They
showed an increased number of positive tests with a similar
rate of complications. Hamm et al (987) reported data com-
piled from 151,949 after AMI in 570 institutions; 28,052
symptom-limited test vs. 96,695 low-level test showed similar
overall fatality (0.03%). Patients with negative tests can be sent
home under medical treatment. Between 3 and 6 weeks later
an exercise test (full Bruce protocol with or without thallium
201) or exercise echocardiography should be performed. As
many as 35% of patients with a negative predischarge submaxi-
mal exercise test may demonstrate evidence of myocardial
ischemia on a more strenuous testing (589,988). Patients with
negative tests are followed under medical treatment (mortality
at one year ,2%) (989–992); patients with positive tests
should be sent for catheterization (mortality at one year is as
high as 15%) (990).
Patients who cannot exercise may be investigated (with
caution) by pharmacological thallium 201 or dipyridamole
echocardiography or be sent directly to the cardiac laboratory.
They represent 10% to 22% of survivors of AMI. Such patients
have a high mortality rate and a high incidence of recurrent
events (595,842,993–995). If the noninvasive test is negative
they can be followed closely under medical treatment. If
fibrinolytic treatment is contraindicated or no reperfusion is
obtained, those patients should be sent to the cardiac labora-
tory.
This overall approach has certain limitations because, as
has been recognized by Pitt (950), one of the leading author-
ities in nuclear cardiology, the sensitivity and specificity of
myocardial imaging in a low risk population has a high
percentage of false positive and false negative results. Kulick
and Rahimtoola (948) pointed out that a substantial percent-
age of patients (about 17% to 23%) who are at risk for
recurrent AMI or death will fail to be identified by non-
invasive testing. Furthermore they remark that the sensitivity
of exercise testing for the detection of multivessel disease in
survivors of AMI has been ,75%. In a critical analysis of the
noninvasive predischarge test they finally summarized their
comments as follows: from 100 patients, 15 would not be able
to perform the test; of 85 taking the test, the results would be
abnormal in 37 and in 19, inconclusive. Upon the negative
testing, full Bruce protocol after discharge would show that in
nine patients the results would be abnormal. They believed all
those 80 patients should have cine coronary angiography. As
we know, the presence of multivessel coronary artery disease
and the status of the left ventricle are the best predictors of late
survival. The presence of viable myocardium supplied by an
obstructed coronary artery (risk segments) is associated with a
high incidence of adverse cardiac events (600). Without any
doubt only cine coronary angiography can give us the real
picture of the coronary artery in the distribution of lesions.
In summary the low risk group of patients will be given
fibrinolytic agents (Fig. 11). Patients who can exercise have
submaximal exercise tests, and those who show positive results
will be sent to the cardiac laboratory. Patients with single-
vessel disease will be treated with PTCA, patients with mul-
tivessel disease and significant proximal obstruction will be
operated on. Still, some patients will be kept on medical
treatment for the same reasons already mentioned as well as
other patients with severe diffuse coronary arteriosclerosis with
poor distal runoff. Careful analysis of the cine angiography will
determine whether PTCA or CABG are indicated during the
same admission. Still another group of patients will be treated
with PTCA or CABG after a positive test is done between 3 to
6 weeks after the acute event.
In patients who cannot exercise catheterization performed
directly or after a pharmacological test is positive determines
another group in whom PTCA or CABG is indicated. The
same approach is valid for patients in whom thrombolysis is
contraindicated or patients with failed thrombolytic therapy.
Of course these are guidelines for general orientation. Each
patient should be analyzed properly with judgment and definite
criteria in order to reach the best therapeutic decision. Clinical
stratification should be the bench mark. There is enough time
to evaluate patients at low risk after the fibrinolytic treatment
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is instituted. Once again we have to remember that only ;50%
of the culprit arteries will be really open. PTCA and CABG
will be indicated in a large number of patients.
Patients at high risk should be sent to the cardiac laboratory
as quickly as possible. Most of them will be treated during the
early hours with PTCA. Only a very small number are candi-
dates for emergency CABG. Thereafter, careful analysis of the
cine angiograms will determine when CABG should be per-
formed. If recurrent angina appears during hospitalization,
catheterization will be mandatory in this early stage.
Anterior infarctions merit particular attention, because
they carry a higher short- and long-term mortality rate
(382,996); cine angiography will be needed in most of them.
The same is true for non-Q wave myocardial infarction.
Although hospital mortality is low, they have a high incidence
of recurrent ischemia (727,994,997,998) and a high mortality
after hospital discharge (999,1000), associated with severe
residual coronary narrowing. I believe cine coronary angiogra-
phy should be the first choice in the evaluation of non-Q wave
myocardial infarction. Nevertheless a submaximal or symptom-
limited exercise test can be done in patients with non-Q wave
myocardial infarction. The results are similar (985,994,
1001,1002) to those of Q wave myocardial infarction.
Young patients (,50 years of age) have a lower incidence
of extensive coronary artery disease (592,972,1003,1004). Anal-
ysis of the clinical record (familiar dyslipidemia, hypertension,
diabetes, smoking) will determine the necessity of cine angiog-
raphy.
As we already commented, most deaths due to AMI occur
in elderly patients. They have a threefold or greater late
mortality than younger patients (975,1005–1008), mainly as a
consequence of an increased number of multivessel lesions.
There are limited data on the role of noninvasive testing,
because most series have excluded older patients. Moreover, a
significant percentage will be unable to complete satisfactorily
an exercise test after AMI. Therefore, cine angiography should
be considered for older patients who are in good clinical
condition.
One important question remains unanswered: is it possible
to apply the plan that I present at a community level? In 1988
it was established by zip code analysis that 63% and 83% of the
U.S. population live within 30 and 60 minutes, respectively, of
a cardiac laboratory (755). It is probable that the percentage
has increased in recent years. Nevertheless, in 1993 it was
estimated that only 18% of institutions had facilities to per-
form PTCA in the U.S. (10% in Europe) (924) and not all of
these are prepared to perform emergency catheterization.
Therefore, the preliminary answer to the question posed
should be “no.” However, I think it is possible to organize a
strategy by geographical areas in order to obtain adequate
coverage. Patients admitted to the coronary care unit at the
community level may undergo a rapid clinical stratification.
Patients at high risk will be immediately sent to a well-
equipped hospital with a catheterization laboratory and per-
sonnel qualified for both PTCA and CABG. Time can be saved
by having well-trained personnel in the coronary care mobile
units, as suggested by the ACC/AHA Guidelines for patients
with AMI. A preliminary analysis will determine high risk and
need for transfer to a well-equipped hospital.
Patients at low risk will receive thrombolytic therapy at the
community hospital. If they develop postinfarction angina,
serious arrhythmia, significant left ventricular failure, or a
submaximal exercise test is positive, they could be transferred
to the qualified centers. The feasibility of this approach has
already been demonstrated by a health maintenance organiza-
tion program in the areas of Los Angeles and San Diego (707).
An analysis of the NRMI showed that early primary PTCA
was performed in 5.9% of the patients and emergency CABG
in 0.6%. During hospitalization, 20.5% underwent PTCA and
10.8%, CABG (personal communication, W. J. Rogers). In the
Figure 11. Guidelines for man-
agement of low-risk patients with
acute myocardial infarction.
Echo 5 echocardiography; FBP 5
full Bruce protocol; LBBB 5 left
bundle branch block; Spect 5
single-photon emission com-
puted tomography; T1 201 5
thallium-201; other abbreviations
as in Figures 5 and 6.
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GUSTO trial (1009,1010), of 21,772 patients, 72% underwent
angiography before discharge and of those 59% underwent
revascularization (70% PTCA and 30% CABG). The TIMI
IIIB trial (1011) presented similar results: in the conservative
strategy (733 patients) 64% had catheterization within six
weeks. Revascularization was performed in 49% (PTCA in
26% and CABG in 23%). These three trials can give us a
general idea of the present approach among patients with
AMI.
We can conclude that at present PTCA and thrombolysis
are at the front line for emergency treatment in patients with
AMI. CABG is indicated in a small number of patients in the
first 24 hours, but later there is adequate opportunity for its
application.
Final Conclusions
The early period of CABG was characterized by widespread
controversies. If we summarize the first decade, it is obvious
that the benefit of CABG was related to the severity and
number of the obstructions of the coronary lumen and benefits
increased with the number of severe coronary lesions (at the
Cleveland Clinic we were always referring to proximal obstruc-
tions). It is difficult to deny that at least in left main trunk
obstruction and triple-vessel disease the evidence was quite
clear. With increased experience, the surgical mortality and the
incidence of perioperative myocardial infarction decreased
significantly, even though the surgical population started to
include patients with abnormal ventricles.
Our medical colleagues were demanding randomized trials.
The VA Trial and the European Study were the first to appear.
The VA Trial was not properly organized and hospitals with
different mortalities (some of them unacceptable) were com-
bined. Nevertheless, clinical risk stratification was valuable,
even though it served to demonstrate that patients that were
excluded from the trial were the most benefited. The VA Trial
confirmed the opinion that patients with left main trunk
obstruction and patients with triple-vessel disease, particularly
those with an abnormal left ventricle were candidates for
operation. The benefit was remarkable in the high-risk group.
The European Study only accepted patients with normal
ventricles. For the first time patients with double-vessel disease
with 75% obstruction of the proximal segment of the anterior
descending artery showed improved survival with CABG.
In 1980, when the results of the Consensus Development
Conference were released, it appeared that the controversies
between cardiologists and cardiovascular surgeons would di-
minish. But in 1993 the results of the CASS randomized trial
stirred up the dispute. I think the outcome of the 4.7% low-risk
group of patients included in the randomized trial could not be
applied to the overall population of patients with coronary
disease.
Utilization of internal mammary grafts definitely improves
surgical results, and it also improves long-term survival. Arte-
rial bypasses certainly are the grafts of choice. Radial, epigas-
tric and gastroepiploic arteries allow multiple bypasses by
composite arrangements. CABG, performed in millions of
patients, has contributed in part to the decline of coronary
artery disease mortality (1012).
The introduction of PTCA in 1977 deepened our responsi-
bilities. Now our patients can follow three different roads. We
should know all of them in detail to select the proper treat-
ment, avoiding any personal preference: treatment selection
must be based only on scientific evidence.
In patients with single-vessel disease, PTCA is indeed the
initial treatment preferred in many cases. In patients with
multivessel disease the landmarks are not clear. Analysis of the
five principal randomized trials (BARI, EAST, CABRI, GABI
and RITA) clearly demonstrates that they compare a low-risk
double- and triple-vessel disease population. Even though the
data sometimes are incomplete, meticulous analysis conclu-
sively showed (mainly in the BARI trial) that patients included
in the randomized trial comprise only a small proportion of
patients with multivessel disease. Certainly this is not the
population that we are facing every day in the operating room.
The classification of single-, double- and triple-vessel dis-
ease is totally inadequate today. Readings of cine coronary
angiograms should specify the number of proximal obstruc-
tions and the size of the coronary arteries and which vessel is
dominant. Ringqvist’s classification and Myers’ contributions
are extremely valuable in this regard. If we want to compare
different therapeutic approaches it is time to realize that the
classification of single-, double- and triple-vessel disease only
gives us a partial and unsatisfactory overview of the coronary
anatomy (383).
The problem of silent ischemia has been evaluated in the
analysis of asymptomatic patients. I am sure that such cases
will increase in our daily practice. Exercise tests are common
during yearly routine checkups. New technology will help in
the early detection of coronary arteriosclerosis. Noninvasive
quantification of myocardial blood flow by PET (1013), ultra-
fast computed tomography (1014–1016), and ultrasound to
detect early coronary plaques in carotid abdominal and periph-
eral circulation (1017,1018) will help us to screen asymptom-
atic patients with coronary atherosclerosis.
In patients with AMI, fibrinolytic therapy and PTCA are
the initial choices. I emphasized the limitation of the former,
even though it can be applied at the community level, only
;50% of the arteries are really open. TIMI 2 flow should be
considered unfavorable at early and late results. Surprisingly,
in a recent contribution from the GUSTO Trial (1019) TIMI 2
flow is reported together with TIMI 3 flow. Recurrence of
angina, reinfarction and reocclusion are common during and
after hospitalization.
Angioplasty requires well-organized centers with trained
personnel. The mortality is related with the experience of the
operator. No doubt many high-risk patients should be treated
primarily by angioplasty, particularly patients in shock. The
preliminary experience with stents is promising, mainly after
Colombo’s contribution. I presume this will be the treatment of
choice, of course at a significantly high cost.
Surgery within six hours will be reserved for a small number
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of patients at high risk including some in cardiogenic shock but
CABG should be indicated in a large number during the
subacute phase after fibrinolytic therapy or successful PTCA.
Neither modifies the underlying coronary artery disease and
the long-term outlook will be related closely to the location,
severity and extent of residual disease including the TIMI 2
flow in the infarct-related artery. CABG before discharge is
indicated in recurrent angina, reinfarction and reocclusion
after thrombolytic therapy or PTCA. Of course, careful anal-
ysis of the cine angiography will determine in which patients
this approach should be utilized. So far all these considerations
are related to Q wave myocardial infarction.
To prepare this analysis of CABG, I personally reviewed
hundreds of papers, and sometimes it was difficult to reach
conclusions quickly. As an example Emond et al (1020)
presented a long-term survival of medically treated patients in
the CASS registry: 23,467 were included, although they indi-
cated that, 10,976 eventually had CABG (9,013 within the first
year). The figures from the different tables are confusing. As
an example, if we analyzed Figure 12, we would realize that
1,384 is not 71% of 6,536. If that were the relationship, the real
number at 0 year should be 1,949. Therefore, 4,587 would be
missing (in my belief most were operated on). Consequently,
this figure does not represent strictly follow-up survival of
patients under medical treatment.
Zhao et al. (554) analyzed the effectiveness of revascular-
ization in the EAST trial. It is not simple to understand clearly
what they mean by index lesion, index segments and high
priority index segments. Figure 1 (of that paper) is difficult to
analyze. Furthermore, in Table 3 (also from that paper) the
follow-up at one and three years of complete and incomplete
revascularization is given for the total number of patients
(CABG and PTCA together). It would have been valuable to
know the figures for CABG and PTCA separately in the four
categories into which patients were placed. The success rate
(76%) is calculated only in relation to the 360 lesions for which
PTCA was attempted. The total number of lesions is 471.
Therefore only 56% of them were dilated. In comparison, from
474 lesions, CABG was “attempted” in 464 (98%) based on
operative report. Certainly, instead of “attempted,” the proper
term is “performed.”
I doubt whether the findings of some reports can be applied
in daily practice. As an example, in 1994 the CASS compared
253 patients surgically treated with 47 medically treated (all
had .70% left main trunk obstruction plus a severe obstruc-
tion of a significant right coronary artery) (1021) and 105
surgical with 30 medical patients with left main equivalent
disease plus a severe obstruction on the right coronary artery
(1022) showing that they had similar survival at 16 years. A
reproduction of a cine coronary angiography typical of this
kind of patients is included (Fig. 13). How many of us will
advise medical treatment?
At present in order to understand most contributions,
particularly clinical and randomized trials, a physician has to
be a mathematician. Risk reduction and odds reduction are not
enough; at least Kaplan-Meier curves, hazard ratio, Cox pro-
portional hazard regression, stepwise procedures, log rank test,
propensity score, etc. are necessary. The modified Mantel-
Haenszel method seems to be the most appropriate to organize
a meta-analysis. “In essence, the observed minus expected
values of the treatment group for each trial are summed and
then divided by the sums of the square root of the sum of the
variances for each trial:
Z 5 S~Oi 2 Ei!/ÎSVi,
where Oi is the observed response in trial i; Ei is the expected
response in trial i; and Vi is the variance in trial i (1023). Still,
we cannot deny their contribution. However, many times they
have been utilized to justify previous personal expectation.
Risk reduction represents the variation percentage between
the treated group and the control group rather than their
absolute difference. It can be seen in Table 19 that one can
obtain the same values of risk reduction over a broad range of
absolute differences (0.1% to 100%), i.e., if risk reduction is
presented out of context, the clinical significance can be
misinterpreted.
Figure 12. Survival rates for medically treated CASS trial pa-
tients by number of diseased vessels (DISVES [1, 2, 3]), with
three categories for zero-vessel disease: normal (norm), minimal
(min) and moderate (mod). CASS 5 Coronary Artery Surgery
Study; stat 5 statistic. Data from Emond et al. (1020).
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Risk reduction also depends on the control group value
because the percentage is calculated from this value. Table 20
lists different control values with the same absolute differences,
showing that risk reduction is in inverse proportion to the value
of the control group. The higher the control value, the lower
the value of risk reduction.
We can compare three trials where risk reduction is shown
(375,1024,1025). In Table 21 no doubt 23.08% vs. 3% and
14.8% vs. 1.1% are more impressive. Utilizing t-PA we save
only 1 patient in 100. Nevertheless, for the GUSTO investiga-
tors, utilizing risk reduction the difference is “highly signifi-
cant.” In my opinion it is highly significant if we take into
account that currently t-PA treatment costs approximately
$2,000 and SK $350. If risk reduction is applied to the CASS
randomized trial data (Fig. 14), no doubt the first indication for
CABG should be patients with single-vessel disease.
Randomized trials have developed such high scientific
stature and acceptance that they are accorded an almost
religious sanctification (1026). A critical analysis has been done
by Feinstein (1027). After several considerations he concluded
that
Randomized trials are too difficult, too expensive, or too
controversial for routine use in answering all the clinical
questions that will arise in the future for a burgeoning diagnos-
tic and therapeutic technology. Whether we like it or not, most
of our future decisions about medical practice, health care, and
scientific technology will have to be made without evidence
from randomized trials. To acknowledge this reality requires no
loss of reverence, allegiance, or respect for the primacy of
randomized trials as a “gold standard” in scientific research.
Can the overall results of clinical and randomized trials be
applied to all patients? The answer has been given by Rothwell
(1028):
Strictly speaking, the results of clinical trials cannot be
applied to individuals. A single patient cannot experience a
50% reduction in death or a 20% improvement in survival. Such
risks can only be calculated from analysis of groups of similar
patients. However, patients included in a clinical trial are
heterogeneous and may, for example, differ in the severity of
illness and consequently in the absolute risk of a poor outcome.
Treatments for patients with coronary arteriosclerosis have
changed so rapidly that even the most recent data from a large
trial may be obsolete. As a consequence new trials have been
appearing. Cheng compiled 244 in 1992 (1029), approximately
900 (1030) in 1994, and over 1,300 in 1996 (1031). And many
more will come. We can mention internal mammary artery
graft to the anterior descending branch of the left coronary
artery performed with a minithoracotomy approach vs. PTCA
of proximal lesion on the same branch, or multiple arterial
composite bypass grafts vs. angioplasty with new devices. The
evaluation of stents in AMI is already underway by the
multicenter PAMI Stent Pilot Study.
I believe clinical and randomized trials with proper inter-
pretation have been valuable. Nevertheless, they cannot re-
place clinical judgment. If relied on exclusively they may be
Table 19. Analysis of Risk Reduction
Control
(%)
Treatment
(%)
Absolute Difference
(%)
Risk
Reduction
0 0 0 50
2 1 1 50
20 10 10 50
50 25 25 50
200 100 100 50
Table 20. Analysis of Risk Reduction
Control
(%)
Treatment
(%)
Absolute Difference
(%)
Risk
Reduction
5 0 5 100
10 5 5 50
20 15 5 25
50 45 5 10
100 95 5 5
Figure 13. Severe obstruction (arrows) of the (A) left main and (B)
right coronary arteries.
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dangerous, as was pointed out by Paul Wood in 1950 (1032):
“Yet there is plenty of evidence to show that we are in danger
of losing our clinical heritage and pinning too much faith in
figures thrown up by a machine. Medicine must suffer if this
tendency is not checked.”
From the beginning I have always emphasized that CABG
is only a palliative treatment (1033). Undoubtedly, develop-
ment in surgical or catheter-based revascularization proce-
dures yielded significant improvements in the care of patients.
Although new technologies will certainly result in further
advances in the diagnosis and treatment of atherosclerotic
lesions, the incidence of coronary heart disease will only be
decreased by proper preventive measures. The general agree-
ment in the medical community about the clinical benefit of
comprehensive risk factor identification and management is
substantiated by data from interventional studies, mainly in the
field of blood lipids modification (1034–1042). Different cho-
lesterol lowering interventions using either life style changes
and hypolipidemic drugs (1034,1043) resulted in a reduction of
the rate of progression or even in a modest reduction of the
size and extent of coronary lesions.
It is highly probable that in regression studies (1044), the
actual anatomical changes have been underestimated. In fact,
plaque changes were documented using angiography, a
method highly valuable to assess coronary disease extension
but rather insensitive to evaluate changes in those lesions that,
although small, are responsible for a large number of acute
coronary events (627,1039,1045–1048) and might respond bet-
ter to a lipid lowering therapy than stenotic, large and mostly
fibrocalcified advanced plaques.
A recent angiographic study, the Regression Growth Eval-
uation Statin Study (REGRESS) added renewed support to
the concept that cholesterol lowering in CHD (coronary heart
disease) patients is beneficial (1049).
Recent studies have demonstrated that a reduction of
LDL-cholesterol is associated in animals and humans with a
distinct endothelial-dependent vasodilatory response, as op-
posed to the vasoconstriction that is evoked in the presence of
hypercholesterolemia (1050–1054). This functional normaliza-
tion might explain the relatively rapid clinical improvement
observed in symptomatic coronary patients after the initiation
of aggressive lipid-lowering therapy (1055), even though sig-
nificant anatomical changes are not reasonably expected at this
time.
Whatever the mechanism involved, either anatomical or
functional, the actual benefit for the patient is to be measured
in terms of clinical changes. In this respect, several early
studies have demonstrated that a favorable lipid modification
is associated with a reduction in cardiovascular morbidity and
mortality (1035,1056). However, only recently could it be
demonstrated that a lipid lowering treatment may reduce total
mortality. The results from the Scandinavian Sinvastatin Sur-
vival Study (4S), have clearly shown a reduction in coronary
mortality by 42% and total mortality by 30% (1057).
The enthusiastic notion that lipid-lowering therapy might
benefit coronary patients even if their basal cholesterol con-
centration is relatively normal (a common finding in coronary
subjects) was recently subjected to scientific evaluation. In the
Cholesterol and Recurrent Events (CARE) study, presented at
the American College of Cardiology (March 1996) (1058)
4,159 post-myocardial infarction patients with a mean total
cholesterol concentration of 209 mg/dl at initial screening
(inclusion criteria: total cholesterol ,240 mg/dl and LDL-
cholesterol 115 to 174 mg/dl) were randomized to receive
pravastatin 40 mg/dl or placebo and followed during a mean
five-year period. Lipid changes, although modest, were accom-
panied by a significant 24% reduction in coronary heart disease
death and nonfatal myocardial infarction. Moreover, active
treatment was associated with a 26% reduction in the inci-
dence of CABG surgery and a 22% reduction in the incidence
Table 21. Examples of Risk Reduction*
Trial Placebo Propanolol SK t-PA MT ST Difference
Risk
Reduction
BHAT 13% 10% 3% 23.08%
GUSTO 7.4% 6.3% 1.1% 14.86%
CASS
1-VD 7% 3.5% 4% 50%
2-VD 6% 5% 1% 17%
3-VD 10.5% 7.5% 3% 28.57%
*Data from references 375, 1024 and 1025. BHAT 5 Beta-Blocker Heart Attack Trial; CASS 5 Coronary Artery
Surgery Study; GUSTO 5 Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries; MT 5 medical
therapy; SK 5 streptokinase; ST 5 surgical treatment; t-PA 5 tissue-type plasminogen activator; VD 5 vessel disease.
Figure 14. Risk reduction for three clinical trials. BHAT 5 Beta-
Blocker Heart Attack Trial; GUSTO 5 Global Utilization of Strep-
tokinase and TPA for Occluded Coronary Arteries; other abbrevia-
tions as in Figures 5 and 8.
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of angioplasty. Interestingly, the benefit of aggressive therapy
seemed to be limited to patients whose baseline LDL-
cholesterol concentration was greater than 125 mg/dl, a figure
that fits well with the current U.S. guidelines (1059) where
drug therapy is suggested in secondary prevention if LDL-
cholesterol concentration remains above 130 mg/dl after di-
etary therapy.
Currently only 15% to 25% of patients who had CABG or
PTCA undergo intensive cholesterol lowering and risk man-
agement programs (1060). Furthermore, the lack of adequate
control extends to most other risk factors, including blood
pressure, body weight, cigarette consumption and glucose
levels. Therefore, it seems reasonable to make efforts to
evaluate more carefully the many negative factors (skepticism
in patients or doctors, motivation of patients, insufficient
patient health education, inadequate risk factor detection or
chronic management, costs of preventive treatments, etc.) that
might account for the unreasonable gap between the medical
enthusiasm devoted to acute interventions and the meager
efforts currently devoted to secondary prevention.
Significant advances have been made in our knowledge of
the pathogenesis of coronary artery disease (1036,1061) and
certainly the last battle will be gained finally in the laboratories,
mainly through molecular biology.
I cannot finish this presentation, perhaps my last compre-
hensive one in medicine, without some ethical considerations.
I have participated in innumerable international meetings in
different parts of the world and many times I had the impres-
sion that the discussions were held only to defend the income
of the participants. Gorlin (1062) has clearly pointed out that
there is an inherent conflict of interest for both practitioners
and hospitals in the performance of these interventional pro-
cedures. They are remunerative. Thus, we must be scrupulously
conscientious in ensuring that we are not performing them to
fill our hospital beds and to support our practices. Self-referral
is an obvious ethical mistake.
The last contribution from the GUSTO trial (1063), utiliz-
ing the classification-and-regression-tree model, demonstrated
that the guidelines for treatment of acute myocardial infarction
have not been followed:
1. Facilities for performing cine angiography and angio-
plasty within a hospital determine the indication. As an
example, if the hospital does have facilities, 81% of the
patients will have the chance of undergoing catheterization; if
the hospital does not have these facilities, the chance will
decrease to 63%. There are other contributions that confirm
these data (1009,1064,1065).
2. Catheterization was performed mainly among patients at
low risk who, as we know, have a positive outcome. Patients at
high risk have similar chances to undergo catheterization.
3. Exercise tests, very important to delineate prognosis,
were performed in less than 30% of the patients.
What is more serious, after adjustment for the severity of
illness, rural and teaching hospitals were less likely to perform
angiography, whereas larger hospitals and those owned by
investors were more likely to do so.
In another recent publication, Spertus and coworkers
(1066) came to a similar conclusion. In an analysis of 4,823
infarct survivors, they found that, except for recurrent angina,
clinical variables predictive of higher mortality were associated
with a lower likelihood of angiography and angioplasty. When
evaluating other factors that may influence the decision to
perform catheterization, angioplasty or surgery in patients with
acute myocardial infarction, Spertus remarked that fears of
malpractice, types of patient employment and physician reim-
bursement may be important in the final approach.
Pilote and collaborators (1063) conclude that
these findings point to a divergence between an ideal decision-
making strategy and the reality of clinical practice. In many
cases the convenience of having facilities available seems to
outweigh the needs of the patient. Finally, practitioners appear
to be selecting the patients likely to have good procedural
outcomes rather than those who would derive the most benefit
from a procedure. In an ideal world, clinicians would develop
an overall estimate of the likely outcome given one treatment as
compared with another, and would preferentially allocate re-
sources to patients with more potential for benefit.
I think it is time to pause and think deeply about our duties
and responsibilities. In 1992 when I delivered the honorary
lecture at the American Association for Thoracic Surgery
meeting, I presented what I believe the principal characteris-
tics of a prospective cardiovascular surgeon should be, and the
ten commandments of a master surgeon. The principal thrust
was that the person of vital importance is the patient, who
should enjoy privileges and our total devotion. We must
demonstrate responsibility, energy, intensity and enthusiasm
for the work at hand. Cardiovascular surgery demands total
dedication and sacrifice. We should have the judgment and
responsibility to make informed decisions and humility to ask
for help when we consider it advisable, recognizing the need to
learn from others. We are part of a team where academic
freedom is essential. New ideas should be discussed, avoiding
pressures and bias and with ethical and moral integrity.
I express my gratitude to William Proudfit, MD for reviewing the manuscript and
for his valuable and innumerable suggestions; Ricardo Armentano, PhD for
assistance in the mathematical analysis; Claudia Saladino for helping me in the
search of articles throughout the literature; and Diana Truden for typing and
retyping the manuscript with untiring dedication.
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